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Abstract
Natural hosts of simian immunodeficiency virus (SIV) are African primates that have coevolved with
species-species SIVs and do not progress to AIDS despite high viral loads. This is in stark contrast to the
immunodeficiency observed in infection of “non-natural” hosts of SIV/HIV, Asian macaques and humans.
Certain critical CD4+ T cell subsets and anatomic niches that are required for maintaining immune
system homeostasis and function are infected less frequently in natural hosts than in non-natural hosts,
suggesting that the determinants of virus target cells contribute to the outcome of infection. SIV and HIV
target cells are largely defined by the expression of the receptor CD4 and a coreceptor. Our lab recently
discovered that the entry coreceptor CCR5 is dispensable for SIV infection of the natural host sooty
mangabey (SM), and then identified CXCR6 as an additional coreceptor for this SIV. In this thesis, I
defined entry coreceptors of a second natural host virus, SIVagmSab that infects sabaeus African green
monkeys and found that CXCR6 was a robust coreceptor for this virus as well. I also investigated
coreceptor use by the HIV-1 forerunners: the natural host virus SIVmus that infects mustached monkeys
and crossed into chimpanzees; and SIVcpz that infects chimpanzees and causes AIDS-like disease and
crossed into humans to found HIV-1. SIVmus infected cells expressing CXCR6 and CCR5, while SIVcpz
was restricted to use of CCR5, indicating that loss of CXCR6 use coincided with the emergence of
pathogenesis in this lineage. Lastly, I defined expression of CXCR6 on SM lymphocytes, and found little or
no CXCR6 expression on CD4+ T cell subsets that are critical in lymphocyte homeostasis, but enrichment
on replenishable effector memory CD4+ T cells. CXCR6+ CD4+ T cells were largely distinct from CCR5+
CD4+ T cells, thus forming a previously unappreciated SIV target cell population in SM. These data
support a model where use of CXCR6 is a common feature among natural host SIVs that targets the virus
towards more expendable cell subsets, and away from critical subsets and anatomic niches that are
required to maintain immune system function, thus permitting high viral replication without
immunodeficiency.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Ronald G. Collman

Keywords
Coreceptor, CXCR6, Simian Immunodeficiency Virus, SIV Natural Host, Virus Entry

Subject Categories
Virology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2793

WIDESPREAD USE OF CXCR6 FOR ENTRY BY NATURAL HOST SIVS: IMPLICATIONS FOR
CELL TARGETING AND INFECTION OUTCOME

Katherine S. Wetzel
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2017

Supervisor of Dissertation
____________________________
Ronald G. Collman, M.D.
Professor of Medicine

Graduate Group Chairperson
____________________________
Daniel S. Kessler, Ph.D., Associate Professor of Cell and Developmental Biology

Dissertation Committee:
Frederic D. Bushman, Ph.D., William Maul Measey Professor and Chair of Microbiology
Michael R. Betts, Ph.D., Associate Professor of Microbiology
James A. Hoxie, M.D., Professor of Medicine
Scott E. Hensley, Ph.D., Associate Professor of Microbiology

Dedication

To my parents, Bruce and Peggy Sheehan, and my husband, Chris Wetzel, who have
always supported my pursuit of learning.

ii

ACKNOWLEDGEMENT

Thank you to my thesis mentor, Dr. Ron Collman, for his enthusiastic support and mentorship
throughout my time in his lab. I’d also like to thank my thesis committee: Drs. Rick Bushman,
Scott Hensley, Jim Hoxie and Mike Betts for their mentorship and experimental advice, as well as
Collman lab members past and present: Sarah Elliott, Nick Francella, Yanjie Yi, Anjana Yadav,
Ize Imai, Melanie Duncan, Vince Knecht, John McGinniss, Aurea Simon Soro, Arwa Abbas,
Nadeene Riddick, Dino Romero, Ezekiel Bello, Anya Bauer, Farida Shaheen, Vanessa Marsh
and Steven Bryan, who have offered technical and moral support throughout my tenure at
UPenn.

The Shaw/Hahn, Betts, Bushman, Hoxie, Cohen/Eisenberg and Bar labs were sources of
valuable advice, expertise and support. I’d especially like to thank Fred Bibollet-Ruche, Ranjit
Warrier, Emily Roberts and Kyle Bittinger. I am also grateful to Sabine Baxter in UPenn Cell
Center Services for her contribution to the generation of the anti-CXCR6 antibody 20D8. This
thesis work would not have been possible without generous sharing of samples from our
collaborators: Drs. Guido Silvestri, Mirko Paiardini, Martine Peeters, Michaela Muller-Trutwin,
Cristian Apetrei and Ivona Pandrea. I would also like to thank all involved with the Cell and
Molecular Biology graduate group, MVP, the Microbiology Department, and the Center for
Teaching and Learning. Lastly, I’d like to thank my funding, particularly the training grant in HIV
Pathogenesis: 2T32AI007632

iii

ABSTRACT
WIDESPREAD USE OF CXCR6 FOR ENTRY BY NATURAL HOST SIVS: IMPLICATIONS FOR
CELL TARGETING AND INFECTION OUTCOME
Katherine S. Wetzel
Ronald G. Collman, M.D.

Natural hosts of simian immunodeficiency virus (SIV) are African primates that have coevolved
with species-species SIVs and do not progress to AIDS despite high viral loads. This is in stark
contrast to the immunodeficiency observed in infection of “non-natural” hosts of SIV/HIV, Asian
macaques and humans. Certain critical CD4+ T cell subsets and anatomic niches that are
required for maintaining immune system homeostasis and function are infected less frequently in
natural hosts than in non-natural hosts, suggesting that the determinants of virus target cells
contribute to the outcome of infection. SIV and HIV target cells are largely defined by the
expression of the receptor CD4 and a coreceptor. Our lab recently discovered that the entry
coreceptor CCR5 is dispensable for SIV infection of the natural host sooty mangabey (SM), and
then identified CXCR6 as an additional coreceptor for this SIV. In this thesis, I defined entry
coreceptors of a second natural host virus, SIVagmSab that infects sabaeus African green
monkeys and found that CXCR6 was a robust coreceptor for this virus as well. I also investigated
coreceptor use by the HIV-1 forerunners: the natural host virus SIVmus that infects mustached
monkeys and crossed into chimpanzees; and SIVcpz that infects chimpanzees and causes AIDSlike disease and crossed into humans to found HIV-1. SIVmus infected cells expressing CXCR6
and CCR5, while SIVcpz was restricted to use of CCR5, indicating that loss of CXCR6 use
coincided with the emergence of pathogenesis in this lineage. Lastly, I defined expression of
CXCR6 on SM lymphocytes, and found little or no CXCR6 expression on CD4+ T cell subsets
that are critical in lymphocyte homeostasis, but enrichment on replenishable effector memory
CD4+ T cells. CXCR6+ CD4+ T cells were largely distinct from CCR5+ CD4+ T cells, thus
forming a previously unappreciated SIV target cell population in SM. These data support a model
where use of CXCR6 is a common feature among natural host SIVs that targets the virus towards
more expendable cell subsets, and away from critical subsets and anatomic niches that are
required to maintain immune system function, thus permitting high viral replication without
immunodeficiency.
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CHAPTER 1

Introduction
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Introduction to HIV-1 and AIDS
Nearly forty years after its emergence, Acquired Immune Deficiency Syndrome (AIDS) remains a
major public health threat, causing the death of over 1 million people in 2015 worldwide (1). AIDS
is marked by the deterioration of the immune system, defined by the occurrence of opportunistic
infections due to this immunodeficiency and CD4+ T cell loss. Human immunodeficiency virus
type 1 (HIV-1) was identified in 1983 (2-4) as the etiologic agent that causes the majority of AIDS
cases, while HIV type 2 (HIV-2), a related virus largely confined to West Africa, accounts for few
cases (5).

In 2015, the most recent year for which data are available, 36.7 million people

worldwide were living with HIV-1, and 2.1 million people were newly infected (6). The United
States population accounts for 1.2 million infected patients (as of 2013) and an estimated 37,600
new HIV-1 infections (as of 2014) (7).

HIV is transmitted to a new host when a bodily fluid containing the virus (blood, semen, vaginal
secretions, or breast milk) comes into contact with a mucosal surface of the genital or
gastrointestinal tract, or via direct contact to blood by intravenous drug use or needle stick (8).
Most new infections are established by a single virion, termed transmitted-founder viruses (9-13).
While early post-transmission events are hard to study in detail, it is known that the virus must
infect a cell expressing the virus receptor and a coreceptor at or near the mucosal surface, which
is followed by focal, then systemic, virus replication. The virus life cycle requires integration into
the host genome; as such, an infected person remains infected for their lifetime. After up to one to
two weeks of undetectable viral replication, acute HIV-1 infection presents with flu-like symptoms,
7

and virus titers expand to 10 copies or more of viral RNA per milliliter of blood (Figure 1.1). After
several more weeks, viral load declines roughly 100-fold with the emergence of the adaptive
immune response to the virus and depletion of virus target cells, and reaches a set point. This
acute infection is followed by a chronic phase that can last several years or decades, where viral
loads are steady or slowly rising, and the immune system remains largely intact. Eventually,
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patients who are not treated with antiviral drugs will suffer a loss of immune system function
marked by reduced CD4+ T cell counts that results in the emergence of opportunistic infections,
thus marking the development of AIDS (Reviewed in (14)).

HIV/SIV genome and replication
HIV is a member of the retrovirus family, as it is enveloped and encodes a single stranded RNA
genome that replicates through a DNA intermediate.

It is closely related to simian

immunodeficiency virus (SIV), a family of species-specific viruses that infect nonhuman primates
(NHP). Both HIV and SIV are more specifically termed lentiviruses due to the long incubation
periods in their hosts. The main genome structure of HIV and SIV are typical of retroviruses in
that they encode gag, pol and env genes, flanked by long-terminal repeats (LTR) (Figure 1.1).
gag gene products include the structural components of the virion, such as the capsid and matrix
proteins, while pol encodes the virus enzymes: integrase, protease and reverse transcriptase.
The env gene encodes the virus glycoprotein that interacts with cell surface proteins to permit
entry. In addition to the three main genes, HIV and SIV encode tat, which promotes transcription
from the LTR, and rev, which is required for export of unspliced and partially spliced viral RNAs
from the nucleus (15, 16). Finally, the HIV and SIV genomes contain a variety of accessory
genes that encode for proteins that promote infectivity within host cells, largely by antagonizing
host restriction factors including APOBEC3G, TRIM5a, SAMHD-1 and tetherin. The specific
genes contained in each genome and roles thereof vary between different HIVs and SIVs,
yielding the three virus groups shown in Figure 1.2. All HIV and SIVs encode nef, vif and vpr,
although these proteins can have different functions between different lineages of SIV (Reviewed
in (17)). In addition, HIV and its relatives also encode vpu, while HIV-2 and its relatives encode
vpx (Figure 1.2). Some SIV genomes contain neither of these genes.

HIV and SIV enter cells by first binding to a receptor, CD4, using the virus surface glycoprotein
Env. On the virion, Env forms a trimer of heterodimers made up of gp120, the surface unit that
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consists of 5 conserved regions and 5 variable loops, and gp41, the fusion peptide. CD4 binding
changes the conformation of Env and reveals the coreceptor binding site. Env then binds the
coreceptor, which is a seven transmembrane G protein coupled receptor (7TMR) such as the
chemokine receptor CCR5, to initiate further conformational changes that promote fusion of the
viral and cellular membranes to deliver the viral genome (Figure 1.3) (18). Virus target cells that
express both CD4 and a 7TMR coreceptor include CD4+ T cells and macrophages of the immune
system.

Post-fusion, the reverse transcription of the RNA genome to DNA by the virus reverse
transcriptase begins, and the capsid disassembles (likely simultaneously, although the precise
order of events is debated in the field). The DNA enters the nucleus as part of the preintegration
complex, and integrates preferentially into actively transcribed genes using the virus integrase.
Virus replication is initiated from the LTR, and RNAs for host proteins as well as the genome for
nascent virions are transcribed.

HIV/SIV assembles at the plasma membrane, and budding

occurs. Once the virus buds, the virus protease cleaves the immature structural proteins to give
rise to the mature virion (15, 16).

Pathogenesis of HIV-1 infection and the animal model infection SIVmac
Productive HIV-1 infection results in death of the target CD4+ cell (19-21). However, viral load is
an incomplete predictor of the severity of disease course, suggesting that immunodeficiency is
not solely due to direct virus cytopathic effect (22). Instead, a stronger correlate of disease
progression and CD4+ T cell loss is the frequency of activated CD8+ T cells, as measured by
expression of the surface markers CD38 and HLA-DR (22-24).

Other markers of immune

activation associated with disease progression include elevated CD4+ and CD8+ T cell
replication, increased macrophage activation (as measured by sCD14) and elevated inflammatory
plasma markers such as IL-10, among others (25-27). Thus, it is now widely thought that chronic
activation of the immune system that follows HIV-1 infection largely drives CD4+ T cell loss and
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immunodeficiency. Hypothesized mechanisms of this immune activation include loss of CD4+ T
cell homeostasis due to constant need to regenerate lost CD4+ T cells, and disruption of
structure and immune function of the lymph node and gut barrier, the latter of which results in
translocation of microbial products into circulation (27). However, many studies investigating
these mechanisms are correlative, and the relative contribution of these mechanisms, in addition
to others, remains unclear.

The complexity of HIV-1 pathogenicity is evidenced by observation of HIV-1 infected patients on
combination antiretroviral therapy (cART). The introduction of cART in 1996 drastically decreased
the morbidity and mortality for patients who had access and adhere to their daily regimens, with
nearly 50% reduction in AIDS-related deaths in the first several years following cART introduction
in the United States and other developed countries (28). However, those who maintain
undetectable viral loads can still experience enduring immune-mediated complications due to
residual immune activation, such as organ failure or HIV-associated neurocognitive disorders,
despite undetectable viral replication (29-32).

In order to address such complications

therapeutically, it will be necessary to completely define the drivers of immune activation and HIV1 pathogenesis.

A valuable tool for studying HIV pathogenesis and treatment strategies has been experimental
infection of rhesus, cynomolgus and pigtail macaques with SIVmac. SIVmac infection
recapitulates many features of HIV-1 infection described above, such as CD4+ T cell loss and
chronic immune activation, although immunodeficiency arises at a faster rate than what is
observed in HIV-1 infection of humans (33, 34). This model has allowed interrogation of early
infection events, which is rarely possible in HIV-1 infection, as well as a platform for testing
vaccines and other therapies.

5

SIV+ African monkeys do not progress to AIDS
However, the pathogenic phenotype of SIVmac infection of rhesus macaques (RM, Macaca
mulatta), which only occurs in experimental settings, is an exception in regard to SIV infections.
Most simian immunodeficiency viruses (SIVs) belong to a diverse, ancient family of viruses that
naturally infect African, but not Asian or New World, nonhuman primates (NHP). Of the 70 known
African NHP species, 45 species (representing ~90% of those tested thus far) have been
identified as infected with a species-specific SIV (35). These species are termed “natural hosts”
of SIV, as they do not progress to AIDS, in contrast to “non-natural hosts” such as HIV-infected
humans and SIVmac-infected macaques. Of the natural hosts, the sooty mangabey (SM,
Cercocebus atys) infected with SIVsmm and the African green monkey (AGM, Chlorocebus spp.),
infected with SIVagm are the best studied as they are housed in primate research centers in the
United States and abroad. Additionally, AGM of the subtype sabaeus have been surveyed in the
wild, with results supporting asymptomatic infection (36, 37). This lack of pathogenesis is thought
to be the product of at least hundreds of thousands of years of coevolution between virus and
host (36, 38). A fundamental goal of the greater HIV field is to understand how such monkeys are
able to maintain immune system function despite viral replication, and, in addition, how those
features differ in non-natural host infections, which would inform mechanisms of HIV-1
pathogenesis.

Natural host SIV origin of HIV-1 and SIVmac
Although natural host viruses are nonpathogenic in their respective hosts, cross-species
transmission of these viruses into new hosts originated HIV and SIVmac infection (Figure 1.4A).
HIV-1 Group M, the group responsible for the AIDS pandemic, is the result of a cross-species
transmission event where SIVcpz crossed the species barrier into humans from chimpanzees
(39). SIVcpz, which is pathogenic in its host (40), was shown by phylogenetic analyses to be the
product of a recombination event between two viruses that crossed the species barrier into
chimpanzees: SIVrcm and an SIV of the lineage SIVgsn/mus/mon (41). As shown in Figure 1.4B,
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the 5’ half of the virus that encodes gag and pol originates from SIVrcm that infects red-capped
mangabeys (RCM, Cercocebus torquatus), while the 3’ half that encodes env originates from a
virus of the lineage SIVgsn/mus/mon, which infects greater spot-nosed monkeys (GSN,
Cercopithecus nictitans), mustached monkeys (MUS, Cercopithecus cephus) and mona monkeys
(MON, Cercopithecus mona), respectively. The less prevalent HIV-1 groups, groups N, O and P,
also originate from SIVcpz, with O and P first crossing from chimpanzees into gorillas before
infecting humans (42-45). HIV-2, which is less pathogenic than HIV-1, is the product of the crossspecies transmission of SIVsmm, which infects the sooty mangabey, into humans (46). At least 8
different cross-species transmissions from sooty mangabeys into humans have occurred, with
two of these transmissions founding the majority of HIV-2 cases (47-49).

Akin to HIV-2, SIVmac is the product of SIVsmm crossing the species barrier into a new host, in
this case, Asian-origin macaques (46). However, unlike humans, macaques do not naturally
encounter sooty mangabeys, as the former inhabits Asia and the latter Africa. Instead, this crossspecies transmission occurred inadvertently in the California National Primate Research Center
where rhesus macaques and SIV-infected sooty mangabeys were cohoused, and possibly during
the generation of an animal model for kuru that included inoculating rhesus macaques with tissue
homogenate from sooty mangabeys (50). SIVmac was later isolated from animals at the New
England National Primate Research Center who had origins in the California Primate Center (51).
Despite its unusual origin, SIVmac infection of macaques recapitulates many of the features of
HIV-1 infection of humans as mentioned, making it the best animal model to date (52).

Main features that vary between natural and non-natural host infection
SIV-infected natural hosts are distinct from SIVmac-infected macaques and HIV-1-infected
humans due to their lack of disease. However, natural hosts do not avoid disease by controlling
the virus; they maintain viral loads as high, if not higher, than non-natural hosts (similar to viral
loads shown in Figure 1.1), and infected cells turnover at a rapid rate, akin to non-natural hosts
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(53-55). Furthermore, natural host SIVs are not inherently nonpathogenic, as cross-species
transmission can cause immunodeficiency in a new host, as described for the transmission of
SIVsmm into macaques. Therefore, factors beyond viral replication itself contribute to the lack of
pathogenesis observed in natural hosts.

Studies of captive SM and AGM have revealed that these natural hosts do not experience either
the profound CD4+ T cell depletion and the chronic immune activation that are thought to be the
main drivers of AIDS. Comparative studies of these natural hosts to RM and humans have
identified distinct features of benign infection outcomes; these include distinct patterns of infection
among anatomic compartments, namely the lymph node and the gut mucosa, as well as
particular CD4+ T cell subsets.

In non-natural hosts, lymph nodes support substantial virus

replication and are marked by fibrosis and a loss of architecture that impedes normal interactions
between immune system cells (56, 57). In contrast, natural host infections do not damage lymph
node architecture, and virus burden is generally lower, particularly in the follicles (53, 58, 59).
The gut harbors the majority of virus replication in both natural and non-natural host infections
(60-63). A hallmark of non-natural host infection is loss of gut barrier integrity, which permits the
translocation of microbial products such as lipopolysaccharide (LPS) from the intestinal lumen to
the circulation, inciting chronic activation of the immune system (64-66). In natural host infection,
the gut barrier remains intact such that microbial translocation does not occur, and markers of
immune activation return to baseline after acute infection (67-69).

Both within and outside of the aforementioned compartments, certain critical CD4+ T cell subsets
are infected or lost at a lower frequency in natural hosts than in non-natural hosts. HIV and SIV
primarily infect activated and memory CD4+ T cells (70, 71). Less differentiated memory CD4+ T
cells subsets that reside in the lymph node, including central memory CD4+ T cells (Tcm), and
stem-cell memory CD4+ T cells (Tscm), are infected at a lower frequency and turnover less often
in natural hosts than in non-natural hosts (72-75). In fact, the rate of decline of Tcm is a strong
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correlate of the rate of disease progression (76), and it is thought that continued proliferation to
replenish lost Tcm contributes to immune activation as well as the disruption of CD4+ T cell
homeostasis. An additional subset, TH17 cells, which produce IL-17 and IL-22 and are crucial for
maintaining gut immunity and barrier integrity, are lost in non-natural host, but not natural host
infection (77-79). Lastly, T follicular helper (Tfh) cells that mediate lymph node germinal reactions
are infected less frequently in sooty mangabey than rhesus macaque lymph nodes, which likely
contributes to the lack of inflammation and fibrosis observed in this tissue in the former (56).
These anatomic and cellular differences, summarized in Figure 1.5, clearly suggest that the cells
that serve as targets for natural and non-natural host infection differ and therefore contribute to
the divergent infection outcomes observed.

Coreceptor use of natural and non-natural HIV and SIV
As mentioned, HIV and SIV engage a receptor, CD4, which causes the envelope protein (Env) to
change conformation and subsequently bind to the coreceptor, permitting membrane fusion and
entry into cells. These coreceptors are seven-transmembrane G protein-coupled receptors
(7TMRs) whose ligands are usually chemokines. Studies of HIV-1 suggest that Env engages
these coreceptors by binding the N-terminal domain and the second-extracellular loop, in a
manner akin to that of their ligands (80). While 7TMRs are quite diverse at the amino acid level,
they share general characteristics such as their 7 transmembrane topology and a signaling motif
in the second intracellular loop (81).

The discovery of CD4 as the receptor for HIV-1 revealed that it was necessary, but not sufficient,
for viral entry (82). Nearly ten years later, studies finally identified the HIV-1 coreceptors: CCR5
and CXCR4. CXCR4, then termed fusin (83), was identified first, and the discovery of CCR5
quickly followed as a second, and ultimately more frequently used, HIV-1 coreceptor (84-88).
New HIV-1 infections are established by CCR5 (R5) using viruses, and later in infection, viruses
that use CXCR4 exclusively (X4), as well as dual CCR5/CXCR4 using (R5X4) viruses,
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sometimes emerge. The importance of CCR5 (and coreceptors in general) to infection was
underscored by the discovery that humans homozygous for a CCR5-null mutation (CCR5Δ32)
are highly resistant to HIV-1 infection (89-91). Coreceptor use is also tightly linked to
pathogenesis, as the emergence of CXCR4 using strains is associated with a more rapid disease
progression, likely due to a broader range of HIV-1 target cells that express this coreceptor,
particularly naïve T cells, which are critical for immune homeostasis (92).

Natural Host SIVs can use non-CCR5 coreceptors to enter cells
Early studies of both natural and non-natural SIVs quickly identified CCR5 as a common
coreceptor of SIV, but SIVs rarely used CXCR4 (93-95). Other coreceptors, typically of human
origin, were observed to permit SIV entry in vitro, but their relevance was not appreciated given
the rare use of these alternative coreceptors by HIV-1. The most robust of these coreceptors
included CXCR6 (previously called STRL33, Bonzo, or TYMSTR), GPR15 (previously called Bob)
and GPR1, while use of APJ, and CCR3 and others were described less frequently (96-98).

One noted exception occurred in SIVrcm, the natural host virus that infects red-capped
mangabeys (RCM). RCM are frequently genetically CCR5-null due to a common 24-base pair
deletion allele, and SIVrcm evolved to use the coreceptors CCR2b and CXCR6, and not CCR5
(99, 100). However, aside from this exception, CCR5 was thought to be the main SIV coreceptor
in both natural and non-natural host infections.

A link between CCR5 use by natural host viruses and infection outcome was determined when a
survey of various primate species revealed that CCR5 expression on CD4+ T cells was very
limited in natural hosts when compared to non-natural hosts (101). More detailed analyses of SM
CD4+ T cell subsets found that the frequency of CCR5 expression was especially restricted on
Tscm and Tcm cells, providing a mechanism for their observed protection from SIV infection (72,
73). A low frequency of CCR5+ CD4+ cells in infant and juvenile SM and AGM has also been
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correlated with infrequent mother to infant transmission in sooty mangabeys and African green
monkeys (37, 102, 103).

While these observations highlight the importance of coreceptor

expression in defining SIV target cells, they also raise the question of how natural hosts are able
to maintain high viral loads with seemingly limited target cell availability and high turnover of
infected cells.

Several years ago, our lab discovered a 2-base pair deletion CCR5 allele that was present at high
allele frequency (25%) in the sooty mangabey colony at Yerkes National Primate Research
Center (YNPRC), and also present in wild animals native to West Africa (104). When considered
in combination with a previously identified but less common 24-base pair deletion CCR5 allele, it
was discovered that animals homozygous for CCR5-null alleles (n=14) were infected at a similar
frequency to wild type (WT) CCR5 animals (n=97) at YNPRC (Figure 1.6A). Furthermore, these
CCR5 null animals were able to maintain high viral loads of 4.37log10, in comparison to 4.83log
of CCR5-WT animals and 4.65log10 of CCR5 heterozygous animals (n=81) (Figure 1.6B). These
data clearly demonstrated that coreceptors aside from CCR5 must be used in SIVsmm infection
(104).

To determine which 7TMRs might act as additional SIVsmm coreceptors, the lab cloned a panel
of nine candidate coreceptors, in addition to CCR5, from SM nucleic acids (105). To accurately
assess SIV coreceptor usage, it is essential to test viral entry through 7TMRs of the same
species, as single amino acid changes can alter coreceptor functionality (106). The lab tested the
ability of each candidate coreceptor, with SM CD4, to facilitate entry of SIVsmm pseudotyped
luciferase reporter viruses and found that in addition to CCR5, SM CXCR6 is a robust coreceptor
of SIVsmm (Figure 1.6A). GPR15 facilitated modest entry, while minimal entry was observed
through APJ and GPR1. Entry through CCR2b, CCR3, CCR4, CCR8, and CXCR4 was not
observed. This pattern held true for Envs isolated from both CCR5 wild type (FFv and FPm) and
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CCR5-null animals (FNp) (Figure 1.7A), demonstrating that use of non-CCR5 coreceptors is not
specific to virus infecting CCR5-null animals (105).

Use of CXCR6 by SIVsmm for infection of SM primary lymphocytes was confirmed by infecting
peripheral blood mononuclear cells (PBMC) in the presence or absence of the CCR5-blocker
maraviroc (MVC) and the CXCR6-blocker CXCL16, which is the ligand for CXCR6 (Figure 1.7B)
(107). SIVsmm replication was limited when blocking each coreceptor individually, and limited
further when both blockers were used together (mean of 57% for CXCR6 blocking, 53% for CCR5
blocking, and 78% for both together). While the degree of blocking conferred was animal
dependent, these data demonstrate that both CXCR6 and CCR5 are used for SIVsmm entry into
SM PBMC.

Use of these two blockers was not sufficient to completely abrogate SIVsmm entry;

this could be due to use of additional alternative coreceptors, such as GPR15, or incomplete
blocking by maraviroc and CXCL16, as these treatments are specific but incomplete against SM
molecules. In contrast, for the non-natural host virus SIVmac, MVC treatment is sufficient to
block replication in rhesus macaque PBMC (Figure 1.7C) (107). Concordant results have been
found in studies where SIV-infected macaques were treated with CCR5 blockers (108, 109).
Thus, SIVmac is restricted to use of CCR5 as a coreceptor, and like HIV-1, does not use CXCR6
or other alternative coreceptors to infect host cells.

While these studies indicate that use of CXCR6 for entry is a feature of the natural host virus
SIVsmm, but not SIVmac, the breadth of this phenotype among natural host viruses is not known.
It is also not known whether CXCR6 use was a feature of natural host ancestors in the HIV1/SIVcpz lineage, and whether or how it changed during cross-species transmission and
emergence of the pathogenic SIVcpz/chimpanzee and HIV-1/human infections. Furthermore, it is
not known what CD4+ SIV target cells express the coreceptor CXCR6, and thus potentially
support high-level replication in natural hosts without disrupting immune homeostasis.
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Goals of this thesis
In this thesis, I address several key questions and hypotheses raised by the discovery that the
natural host virus SIVsmm uses CXCR6 in addition to CCR5 for entry into sooty mangabey
lymphocytes. First, I investigated the breadth of CXCR6 use by natural host SIVs and
hypothesized that CXCR6 is used by a second natural host virus, SIVagmSab that infects African
green monkeys of the subtype sabaeus (Chapter 2). I found that SIVagmSab also used CXCR6
to enter sabaeus lymphocytes. Secondly, the forerunners of the HIV-1 env are the pathogenic
SIVcpz, and the natural host virus lineage SIVgsn/mus/mon. While HIV-1 is known to use CCR5
and/or CXCR4 for entry, the coreceptor use of its SIV predecessors was undetermined. I
hypothesized that use of CXCR6 by this env lineage was lost through cross-species transmission.
I found that SIVmus could use species-matched CXCR6 like other natural host viruses, but
pathogenic SIVcpz was restricted to use of CCR5 like its direct descendent HIV-1 (Chapter 3).
Finally, while use of CXCR6 by SIVsmm has been demonstrated, the expression of this
coreceptor on CD4+ T cells had not been determined. I hypothesized that CXCR6 would be
expressed on more expendable CD4+ T cell subsets and not on more critical subsets, such as
Tcm, which could permit high viral replication without causing immunodeficiency. As there were
no existing antibodies that detected CXCR6 of any natural host species, I generated such an
antibody. I stained SM memory CD4+ T cells and found that CXCR6 expression was restricted
on Tcm, but enriched on effector memory CD4+ T cells (Tem). Additionally, CXCR6+ CCR5CD4+ T cells formed a distinct subset (Chapter 4). Together, the data presented here
demonstrate that species-matched CXCR6 use is a common feature of natural host viruses, but
absent among non-natural host viruses. Therefore, entry by natural host SIVs is fundamentally
different from entry by non-natural host SIVs. This likely defines distinct target cells between
these two types of infections and contributes to the lack of disease progression observed in
natural hosts.
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Figures

Figure 1.1: Typical progression of HIV-1 infection. Typical changes in viral load (red) and CD4+ T cell
counts (black) are shown for HIV-1 infected individuals over time. Patient-specific variability between CD4+
T cell counts and viral RNA copy numbers is observed. Figure from Fauci AS, Desrosiers RC. 1997.
Pathogenesis of HIV and SIV. In Retroviruses (ed. Coffin JM, Hughes SH, Varmus HE), p. 600. Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, NY. (Modified from Pantaleo et al. 1993a.) Reprinted with
permission from Cold Spring Harbor Laboratory Press.
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Figure 1.2: Primate lentivirus genomes. The three genome structures of primate HIV/SIV are shown. All
viruses encode genes for the structural proteins Gag, Pol, Env (in white), the regulatory proteins Rev and
Tat (grey), and the accessory proteins Vif, Vpr and Nef (green). Primate lentiviruses vary in the presence of
genes for the accessory proteins Vpu (orange), and Vpx (blue). Figure from Sauter D, Kirchhoff F.
Properties of Human and Simian Immunodeficiency Viruses. In: Ansari A, Silvestri G, editors. Natural Hosts
of SIV: Implication in AIDS. 1 ed: Elsevier Inc.; 2014. p. 69-84. Reprinted with permission from Elsevier.
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Figure 1.3: The HIV/SIV Env glycoprotein interacts with cell surface CD4 and coreceptor to mediate
entry. The HIV/SIV Env consists of gp120 and gp41. To enter cells, gp120 first binds CD4. This induces
conformational changes that permit binding of a coreceptor, which is largely mediated by Env variable loop
3. Further conformational changes permit insertion of the fusion peptide of Env gp41 into the host cell
membrane and six-helix bundle formation to permit membrane fusion and delivery of the virus genome to
the cell. Figure from Cold Spring Harb Perspect Med 2012;2:a006866. Reprinted with permission from Cold
Spring Harbor Laboratory Press.
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Figure 1.4: Relationships between natural host and non-natural host SIVs. A. A selection of diverse
African natural host primate species and their SIVs are shown in blue boxes to the left, and dashed arrows
indicate known SIV transmissions into other species. Hosts of pathogenic HIV/SIV infections are shown in
red boxes. Figure modeled after Sharp and Hahn, CSH Perspectives in Med., 2012 (5). B. The genome of
SIVcpz is the product of a recombination event between SIVrcm (grey) and SIVgsn/mus/mon (black). The
origin of the first exons of rev and tat is uncertain, thus shown as striped. Figure 1.3B from reprinted from
Sharp and Hahn, Philos Trans R Soc Lond B Biol Sci., 2010 Aug 27;365(1552):2487-94. Reprinted with
permission from the Royal Society.
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SIVsmm-infected sooty mangabeys (SM) at Yerkes National Primate Research Center (YNPRC) does not
differ based on CCR5 genotype. B. SM at YNPRC have high plasma viral loads whether they have two wild
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Figure 1.7: SIVsmm uses coreceptors in addition to CCR5. A. 293T cells expressing 7TMRs of sooty
mangabey (SM) origin and SM CD4 were infected with luciferase reporter viruses carrying SIVsmm Envs.
Legend indicates the name of the SIVsmm Env and the CCR5 genotype of the SM from which the Env was
isolated in parentheses. B. SM PBMC were infected with SIVsmm D215 in the presence of vehicle alone (no
drug), the CCR5 blocker maraviroc (MVC), the CXCR6 blocker CXCL16, or both blockers together.
Replication was measured by p27 Gag production in the supernatant and data is shown as percent of
replication in the presence of vehicle alone (no drug) at day 7 post infection. C. RM PBMC were infected
with SIVmac239 in the presence of vehicle alone (no drug) or MVC, and replication was measured and data
shown as in (B).
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Entry into Sabaeus African Green Monkey Lymphocytes
Implicates Widespread Use of Non-CCR5 Pathways in Natural
Host Infections
This work was published in the following publication:
Wetzel KS, Yi Y, Elliott ST, Romero D, Jacquelin B, Hahn BH, Muller-Trutwin M, Apetrei C,
Pandrea I, Collman RG. Journal of Virology. 2017;91(4).

29

Abstract
African green monkeys (AGM) and sooty mangabeys (SM) are two well-studied natural hosts of
SIV that do not progress to AIDS when infected with their species-specific viruses despite
maintaining high viral loads. Natural hosts are characterized by a low frequency of CD4+ T cells
expressing the entry coreceptor CCR5. Recent studies from our lab and others have shown that
CCR5 is not required for SIV infection of SM, and that the chemokine receptor CXCR6 permits
entry of the SIV that infect SM in vitro and ex vivo. Furthermore, entry pathways in addition to
CCR5 are used by SIV to infect AGM of the subspecies vervet, and CXCR6 is a robust
coreceptor for this SIV in vitro. Here, I analyzed use of species-matched CXCR6 and other
alternative coreceptors by a third natural host virus, SIVagmSab which infects AGM of the
subspecies sabaeus. I cloned sabaeus AGM CXCR6, CCR5 and eight other candidate
coreceptors and found that CXCR6, CCR5 and GPR15 permitted entry of pseudotypes
expressing a previously characterized SIVagmSab Env, 92018ivTF. Importantly, I also tested
coreceptor use of two novel envs cloned from plasma of wild-infected sabaeus AGM and found
robust CXCR6 use as well.

Finally, blocking entry through CXCR6 with the ligand CXCL16

significantly blocked replication of SIVagmSab92018ivTF in sabaeus AGM lymphocytes,
indicating use of CXCR6 for entry. Furthermore, blocking CXCR6 had a quantitatively greater
impact on infection than did blocking CCR5. Together these data support a paradigm for natural
host infection in which use of CXCR6 (and possibly other coreceptors) is a common feature of
natural host SIVs. Limited expression of CCR5 is seen in natural host CD4+ T cells, and thus
use of CXCR6 by natural host SIVs could target infection towards certain CD4+ T cell subsets
that support viral replication while preserving immune system homeostasis and function.
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Introduction
Over 40 species of African nonhuman primates (NHPs) have been identified as “natural hosts” of
SIV, as evidence suggests they do not progress to AIDS, which is likely due to prolonged
coevolution between virus and host (35). Natural hosts maintain high viral loads and a rapid
turnover of infected cells, like “non-natural hosts” such as Asian macaques infected with SIVmac
(54, 55, 111). Despite this, infected natural hosts maintain normal peripheral CD4+ T cell counts,
maintain gut barrier integrity and immunity and preserve lymph node structure and functions (112,
113). In contrast, non-natural host infection is marked by progressive CD4+ T cell loss, gut barrier
disruption and translocation of microbial products, and lymph node fibrosis and inflammation
(114). Understanding how natural hosts of SIV are able to avoid immunodeficiency is crucial to
define mechanisms of pathogenesis in non-natural hosts, including HIV-1 infected humans.

A key mechanism implicated in the benign outcome of infection in natural hosts is the protection
of certain CD4+ T cell target populations and anatomic niches from infection (and conversely,
viral replication in cells other than those that support infection in hosts that develop AIDS). In the
natural host sooty mangabey (SM, Cercocebus atys), central memory (Tcm) and stem-cell
memory (Tscm) CD4+ T cells, which are required for maintenance of memory T cell homeostasis,
are infected at a lower frequency than in rhesus macaques (RM, Macaca mulatta) (72, 73). Also,
natural host lymph nodes carry a low viral burden, particularly in the follicles and T follicular
helper cells (Tfh), and also maintain their structure and function (53, 56, 58, 59). In infected RM
and humans, lymph nodes carry a high viral burden and are marked by inflammation, fibrosis and
collagen deposition (56, 115). Lastly, infected natural hosts maintain gut barrier and immunity,
likely due to maintenance of Th17 cells (67, 77). In contrast, non-natural host infection is marked
by a loss of gut Th17 cells and disruption of the barrier integrity, causing microbial products to
translocate into circulation and drive immune activation (64-66, 78, 79). Therefore, to understand
pathogenesis, it is essential to define determinants of cell targeting by SIV in natural and nonnatural hosts.
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HIV/SIV target cells are largely defined by the expression of the virus receptor, CD4, and a
seven-transmembrane coreceptor. Historically, CCR5 was thought to be the only coreceptor used
by SIV, although in vitro experiments had demonstrated use of other chemokine receptors
(usually of human origin) for entry (96-98).

Natural hosts maintain a low frequency of CCR5+

CD4+ T cells, suggesting that reduced expression of this coreceptor protected CD4+ T cells from
infection (72, 101). However, this finding also raised the question of how natural hosts are able to
maintain such high viral loads with limited target cell availability and high turnover of infected cells
(54, 55, 111). Recently, our lab identified a common CCR5 deletion allele in SM that prevents
CCR5 surface expression on the cells of homozygous animals (104). Despite this, CCR5-null SM
are frequently infected and maintain viral loads near that of CCR5-wildtype SM, indicating that
non-CCR5 entry pathways are used by SIVsmm. We then identified species-matched CXCR6 as
a robust coreceptor for SIVsmm infection in vitro, and confirmed use of CXCR6 and CCR5 by
SIVsmm to infect SM peripheral blood mononuclear cells (PBMC) using blocking agents (105,
107). A subsequent study of AGM of the subspecies vervet (Chlorocebus pygerythrus, which
inhabit East and Southern Africa) has shown that use of CCR5 is not required for infection of
vervet PBMC, and that species-matched CXCR6 and GPR15 are efficient coreceptors in vitro
(116). Although use of CXCR6 in vervet AGM PBMC infection was not directly examined in that
study, these data suggest that use of coreceptors in addition to CCR5 is a common feature of
natural host SIVs.

Here, I investigated the entry pathways of a third natural host virus, SIVagmSab that infects
sabaeus African green monkeys (Chlorocebus sabaeus, which inhabit West Africa). Previous
studies of SIVagmSab entry have used human coreceptors and CD4 (98). However, knowing that
single amino-acid changes can alter coreceptor use by SIVs (106), I first cloned candidate
coreceptor and CD4 genes from sabaeus AGM cells. Also, many SIVagm isolates have been
passaged on human cells, which could have altered the ability of such viruses to use coreceptors
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of sabaeus origin (117, 118). Therefore, I cloned novel field isolate envs from plasma from
sabaeus AGM that were infected upon their capture in West Africa, and tested these in addition to
a recently described unpassaged SIVagmSab transmitted-founder clone 92018ivTF (119). Since
coreceptor function can depend on its degree of expression, I measured entry across a range of
coreceptor levels (120, 121). Also, I tested coreceptor use at two levels of CD4 expression, in
part because AGM lymphocytes downregulate CD4 (122). Finally, I examined the contribution of
CCR5 and CXCR6 use to SIVagmSab infection of sabaeus PBMC by using blocking agents
against these two coreceptors. I found that sabaeus CXCR6 is an efficient coreceptor of
SIVagmSab, and substantially contributes to SIVagmSab infection of sabaeus PBMC. These data
identify another natural host virus that can use CXCR6 for entry and support an emerging
paradigm of CXCR6 use as a common feature of natural host SIVs.
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Results
Cloning and sequencing of Sabaeus African Green Monkey CD4 and candidate
coreceptors.
Recent work from our lab and others has described use of species-matched non-CCR5
coreceptors by natural host viruses SIVsmm and SIVagmVer (105, 107, 116). I asked whether
the SIV of a third natural host, SIVagmSab of sabaeus AGM, also utilized species-matched nonCCR5 coreceptors for entry with species-matched CD4. I first amplified CD4 from cDNA from two
sabaeus AGM, and isolated two alleles (CD4-30 and CD4-31) that differed from each other by 5
amino acids (Table 1). These alleles contained several previously described AGM CD4
polymorphisms (123, 124), and CD4-30 also contained a unique C-terminal Ser.

Two

polymorphisms fell within domain 1 of CD4, but not within residues implicated in human CD4/
HIV-1 interactions (125). Like other reported AGM CD4 alleles, these alleles share 90% amino
acid identity to human CD4 and are most closely related to the CD4 molecules of other African
green monkey subspecies, including vervet and grivet.

I next amplified APJ, CCR2b, CCR3, CCR4, CCR5, CCR8, CXCR4, CXCR6, GPR1 and GPR15
from genomic DNA or cDNA from one AGM sabaeus using previously described primers that lie
outside the open reading frames of each gene (105). The non-CCR5 coreceptors cloned are
identical in sequence to the genes described in the recently sequenced sabaeus genome (126)
(BioProject: PRJNA215854), except for CCR2b, which contained a conservative V340A
difference. Sabaeus CCR5 is polymorphic, and the allele analyzed here is unique to published
sequences but contains the previously described AGM polymorphisms N57S and R163G (98).

I then aligned the amino acid sequences of these ten sabaeus candidate coreceptors to those of
human, rhesus macaque and sooty mangabey. As shown in Table 2, these coreceptors all vary
in amino acid sequence from those of human, including in the N-terminus and second
extracellular loop (ECL2), the two domains expected to interact with Env, based on studies of
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CCR5 and HIV-1 (80).

These differences underscore the need to use species-matched

coreceptors to accurately assess SIV entry pathways.

The sabaeus candidate coreceptor sequences were more similar to those of other nonhuman
primates than to those of human origin. Some sequences were identical at the amino acid level,
such as GPR1 and CXCR4 (100% amino acid identity between sabaeus AGM and RM) and
CCR4 (100% amino acid identity among sabaeus AGM, RM, and SM). Of note, sabaeus CXCR6
codes a Ser at position 31, as do SM and many other primate species. This residue is associated
with robust use of CXCR6, while an Arg at that position is responsible for the poor coreceptor
activity for SIVmac of CXCR6 for several macaque species, including rhesus, pigtail, and
cynomolgus (106). The sabaeus CXCR6, GPR15 and CXCR4 amino acid sequences described
here are identical to described alleles for vervet AGM (116), while vervet APJ, CCR2b, CCR3,
CCR4, CCR8 and GPR1 have not been reported.

SIVagmSab Envs use non-CCR5 coreceptors in vitro
I then tested the ability of each candidate coreceptor to facilitate SIVagmSab entry in vitro in
conjunction with each cloned CD4 allele. I transfected 293T cells with CD4 and each candidate
coreceptor in turn, and infected cells with a pseudotyped reporter virus carrying the
SIVagmSab92018ivTF Env on a pNL43E-R+Luciferase backbone. The SIVagmSab92018ivTF
env was cloned from the previously described infectious molecular clone that is the
transmitted/founder virus of an intravenous infection with an unpassaged SIVagmSab92018 stock
(119). Pseudotype virus entry was measured by luciferase production in 293T target cells.
SIVagmSab92018ivTF readily entered cells expressing sabaeus CCR5 and CXCR6, and robust
entry through GPR15 was also observed (Figure 1). Low-level entry was measured through
sabaeus GPR1 and APJ.

Notably, although use of human CXCR4 has been reported, no

substantial entry through sabaeus CXCR4 was observed here (119, 127). This pattern of
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coreceptor use was consistent between CD4-30 and CD4-31, and subsequent experiments were
performed using CD4-31 only.

I then sought to expand this analysis to additional SIVagmSab envelopes. However, aside from
SIVagmSab92018ivTF, all available SIVagmSab isolates have been passaged on human cell
lines (117, 118), and it is possible that adaptation occurred that has altered native coreceptor use
patterns. Therefore, I cloned envs from plasma collected from two sabaeus AGM (89042 and
89044) that were already infected upon their capture in West Africa. The sequences of rev, tat,
nef and vpr from SIV infecting AGM 89042 have been described previously (128), while SIV from
89044 has not been previously characterized. I cloned env from vRNA isolated from the two
plasma samples. As shown in Figure 2.2A, the two envs share 78% nucleotide sequence
homology and represent distinct sequences among characterized SIVagmSab envs.

I pseudotyped these SIVagmSab Envs onto a luciferase reporter backbone and tested their ability
to enter cells via the ten sabaeus coreceptors and CD4-31 that I cloned (Figure 2B). Like
92018ivTF, both 89042 and 89044 robustly used CCR5, CXCR6 and GPR15 for entry, with lowlevel entry observed through GPR1. While 89042 showed some use of APJ (like 92018ivTF),
89044 did not enter via this coreceptor. None of the Envs tested were able to use sabaeus
CXCR6, CCR5 or GPR15 independent of CD4. Thus, 92018ivTF reflects the alternative
coreceptor use pattern of diverse SIVagmSab isolates from naturally infected monkeys, although
use of APJ is variable.

Efficient Use of CXCR6 by SIVagmSab92018ivTF occurs at varying CD4 levels
The in vitro experimental conditions used here result in high levels of expression of CD4 and
coreceptor on transfected 293T cells; while these conditions allow easy identification of possible
coreceptors, they provide little information on efficiency of use. Additionally, since coreceptor
function can depend on their level of expression, and AGM lymphocytes downregulate CD4

36

expression as they enter the memory pool (120-122), I tested entry through CXCR6, CCR5,
GPR15, GPR1 and APJ at various expression levels of both coreceptor and CD4.

I titrated the amount of transfected plasmid in tenfold serial dilutions from 250ng to 0.25ug for the
functional coreceptors (CCR5, CXCR6, GPR15, GPR1 and APJ) and then infected cells with the
SIVagmSab92018ivTF luciferase reporter virus. Changes in surface expression as a result of
titration could not be directly measured due to a lack of cross-reactive antibodies for all
coreceptors shown here except for sabaeus CCR5. However, I did a parallel analysis using
human molecules to ensure that the plasmid titration protocol would result in differing levels of
surface expression. Cells were transfected with plasmids encoding human CCR5, CXCR6 and
GPR15 at the same concentrations and stained for analysis via flow cytometry using antibodies
that detect the human molecules. This revealed similar levels of staining for each coreceptor,
and decreasing the amount of plasmid led to decreasing levels coreceptor expression across the
titrations that was similar for the three molecules (data not shown).

As shown in Figure 2.3A, titrating sabaeus CXCR6 and CCR5 down tenfold from 250ng to 25ng
of plasmid did not reduce entry; however, entry through GPR15, APJ and GPR1 all decreased. At
a 1:100 dilution of coreceptor plasmid, entry through CXCR6, CCR5 decreased, and entry
through GPR15 decreased even further, but all remained well above baseline, while entry through
APJ and GPR1 could no longer be detected. Thus, sabaeus CXCR6 and CCR5 permitted entry
quite similarly in all conditions, while entry through GPR15 appeared more sensitive to reduced
coreceptor levels, and entry through APJ and GPR1 even more so.

AGM are known to express low levels of CD4, such that CD4 availability may be a limiting factor
for SIVagmSab entry in vivo (101). Therefore, to test whether these results would reflect a similar
pattern in the context of low CD4 expression, and that high expression of CD4 wasn’t masking
subtle differences in coreceptor use, I performed the same experiment (using CCR5, CXCR6 and
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GPR15) in conjunction with both “high” (250ng, as in Figure 3.3A) and “low” (2.5ng) CD4
conditions. Transfected cells were stained for CD4 expression and a comparable decrease
thereof was observed across the coreceptor conditions (data not shown).

This reduction in CD4 resulted in about 50% reduction in maximum entry for the three
coreceptors (Figure 2.3B-D). However, of the three coreceptors, entry through CXCR6 appeared
least sensitive to reduced coreceptor levels in the presence of low CD4, as entry remained
consistent despite a 100-fold decrease in transfected coreceptor plasmid. This suggests that
reduced CD4 may not be an obstacle for CXCR6 mediated entry. Collectively, these data show
that SIVagmSab entry through sabaeus CXCR6 is as efficient as entry through sabaeus CCR5,
including in conditions of reduced coreceptor and CD4, and sabaeus GPR15 is also used
moderately well.

Maraviroc and CXCL16 specifically but incompletely block entry through Sab CCR5 and
CXCR6
Recently published work from our lab demonstrated that blocking entry through CCR5 using
maraviroc (MVC) and through CXCR6 using recombinant human CXCL16, the ligand for CXCR6,
reduced replication of SIVsmm in SM PBMC, confirming that CXCR6 (in addition to CCR5) is an
entry coreceptor for SIVsmm in primary cells (107). Others have shown that blocking entry
through CCR5 does not hinder replication of SIVagmVer in vervet PBMC, indicating use of nonCCR5 entry pathways by this virus as well (116). Therefore, having shown that AGM sabaeus
CXCR6 functions as a coreceptor in vitro, I asked whether CXCR6 was used by
SIVagmSab92018ivTF for entry into sabaeus PBMC.

First, I asked whether maraviroc and CXCL16 could specifically block entry through AGM
sabaeus CCR5 and CXCR6 respectively in vitro, as these coreceptors vary in amino acid
sequence from human and sooty mangabey homologs (Table 1). I transfected 293T cells with
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plasmids expressing sabaeus CD4 and CXCR6, CCR5, GPR15, GPR1 and APJ, and pretreated
cells with 15um MVC, 500ng/mL CXCL16 or vehicle alone for one hour prior to infection with the
SIVagmSab9201ivTF reporter pseudotype (Figure 4A). Both maraviroc and CXCL16 were
specifically able to block entry through their respective sabaeus coreceptors. However, blocking
was incomplete; 18% entry remained through CCR5 despite MVC treatment, and 11% through
CXCR6 despite CXCL16 treatment.

Therefore, use of these inhibitors is specific, but likely

underestimates the use of each coreceptor by SIVagmSab. Unfortunately, no small molecule
inhibitor or other blocker is available against the orphan receptor GPR15, preventing similar
analysis of this coreceptor.

SIVagmSab92018ivTF uses CXCR6 to enter cells
I then investigated the use of CXCR6 and CCR5 in SIVagmSab infection of PBMC from five
animals. Sequencing of the CXCR6 and CCR5 genes from the monkeys revealed identical
CXCR6 sequences, but divergent CCR5 sequences. The CCR5 amino acid sequences contained
previously described polymorphisms at residues 57, 93, and 163 (129), with three heterozygous
for R93, which has been reported to support SIVagm entry less efficiently (24). No animals
possessed CCR5 sequences predicted to be nonfunctional.

Sabaeus PBMC were stimulated with phytohemagglutinin (PHA) and interleukin-2 (IL-2) and then
pretreated with 15uM MVC, 500ng/mL CXCL16, both blockers together, or vehicle alone, and
infected with replication competent SIVagmSab9201ivTF derived from an infectious molecular
clone. Virus replication was quantified by measuring p27 in the culture supernatant by ELISA. At
day 7 post-infection, blockade of CCR5 resulted in a slight but statistically significant 8%
decrease in supernatant p27 (range: 2-14%; p=0.026 compared with vehicle alone). Blockade of
CXCR6 decreased replication by 36% (range: 22-52%; p=0.004 compared with vehicle alone).
The treatments showed an additive effect, such that replication was decreased 52% when both
agents were used (range: 40-72%; p=0.005 and p=0.001 compared with CXCL16 alone and
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CCR5 alone, respectively). CXCL16 had no effect on infection of RM PBMC by SIVmac239
(which uses RM CXCR6 poorly and enters RM PBMC entirely through CCR5 (107)), nor on
infection of human PBMC by HIV-1 BaL, suggesting that SIVagmSab/sabaeus PBMC blocking by
CXCL16 was not an effect of the chemokine unrelated to entry (data not shown). While this study
only included PBMC from 5 animals, we noticed no obvious defect in replication or blocking due
to CCR5 allele.

These data demonstrate that CXCR6 is used for SIVagmSab entry into sabaeus PBMC.
Furthermore, the blocking studies suggest that while CCR5 is used, the contribution of CXCR6 to
entry is quantitatively greater. It is unclear whether residual infection is due to incomplete blocking
of entry through CCR5 and CXCR6, or use of another coreceptor such as GPR15.
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Tables

CD4 clone:
AGM Sab 30
AGM Sab 31

Rhesus

Sooty

AGM Grivet

AGM Vervet

Human

Macaque

Mangabey

(C. Aethiops)

(C. Pygerythrus)

90.6
90.8

95.4
95.6

95.0
95.2

99.1
99.3

98.9
99.1

Table 1: Sabaeus African Green Monkey CD4 molecules. CD4 was cloned from cDNA from PBMC of
two individual animals, yielding two AGM CD4 clones that are 98.9% identical at the amino acid level
(differing by 5 amino acids). (Table originally printed in Wetzel et al, JVI 2017.)

% AA identity to 7TMR from:
AGM Sab

Rhesus

Sooty

# AA differing from human:

7TMR:

Human

Macaque

Mangabey

NTD

ECL2

APJ
CCR2b
CCR3
CCR4
CCR5
CCR8
CXCR4
CXCR6
GPR1
GPR15

98.7
96.7
93.5
98.6
97.4
94.6
98.6
95.3
98
97.2

99.7
99.2
98
100
99.1
99.2
100
98.8
100
99.4

99.5
99.4
97.2
100
98.9
98.9
99.7
98.3
99.7
99.4

0
2
6
0
2
8
3
6
1
1

1
2
4
1
1
1
1
1
1
2

Table 2: Sabaeus African Green Monkey candidate coreceptors. Seven transmembrane receptors
(7TMR) were cloned from PBMC genomic DNA or cDNA, and the amino acid identity is shown compared
with the human, rhesus macaque and sooty mangabey molecules. Also shown is number of amino acids
differing from the human molecule in the N-terminal domain (NTD) and extracellular loop 2 (ECL2), which
are implicated in coreceptor function based on studies with CCR5 and HIV. (Table originally printed in
Wetzel et al, JVI 2017.)
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Figure 2.1: SIVagmSab92018ivTF Env uses non-CCR5 coreceptors in vitro, independently of CD4
allele. A) 293T cells were transfected with one of two AGM Sab CD4 allele clones and each sabaeus
candidate coreceptor. Cells were infected 48 hours later with the SIVagmSab 92018ivTF Env luciferase
reporter pseudotype. Cells were lysed 72 hours post-infection and luciferase content was measured by
relative light units (RLU). Infections were carried out in triplicate and data (means ± standard deviation) are
representative of 4 replicate experiments. (Figure originally printed in Wetzel et al, JVI 2017.)
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Figure 2.2: Diverse field isolate SIVagmSab Envs use non-CCR5 coreceptors in vitro. SIVagmSab
Envs were amplified from plasma isolated from two wild-infected sabaeus AGM (89042 and 89044). A)
Maximum likelihood phylogenetic tree showing novel envs cloned in this study (89042 and 89044), the
previously characterized env 92018ivTF, and other reported SIVagm Env sequences. Envs used in this
study are boxed, and the two envs cloned here from wild naturally infected animals are indicated by arrows.
Bootstrap values >70% are indicated by an asterisk. The scale bar indicates 0.2 nucleotide substitutions per
site. B) 293T cells were transfected with AGM Sab CD4-31 and each sabaeus candidate coreceptor. Cells
were infected 48 hours later in triplicate with luciferase reporter pseudotypes containing the field isolate
SIVagmSab Envs or the 92018ivTF Env. Cells were lysed 72 hours post-infection and luciferase content
was again measured by relative light units (RLU). Infections were carried out in triplicate and data (means ±
standard deviation) are representative of 3 replicate experiments. (Figure originally printed in Wetzel et al,
JVI 2017.)
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Figure 2.3: SIVagmSab92018ivTF efficiently uses sabaeus CXCR6 at high and low CD4 levels. A)
293T cells were transfected with sabaeus CD4-31 (250ng of plasmid) and each AGM Sab CCR5, CXCR6,
GPR15, GPR1 and GPR15 at tenfold serial dilutions, from 250ng to 0.25ng plasmid. Empty pcDNA3.1 was
used as filler such that cells in each condition were transfected with an equal quantity of DNA (500ng). Cells
were infected 48 hours later with the SIVagmSab92018ivTF Env luciferase reporter pseudotype. Cells were
lysed 72 hours post-infection and luciferase content was measured by relative light units (RLU). B) The
experiment was performed as in panel A, but with two amounts of CD4 (250ng, high and 2.5ng, low) and
ten-fold dilutions of CCR5 (B), CXCR6 (C) and GPR15 (D). Data is normalized to 100% entry based on
RLU at maximum CD4 and coreceptor amounts for each coreceptor. Data represent means ± standard
deviations of three replicate experiments carried out in triplicate. (Figure originally printed in Wetzel et al, JVI
2017.)

44

AGM 293T Blocking

RLU (x106)

A
.

120

No drug

100

MVC
CXCL16

80
60
40
20

1

A

G
PR

E
Ve mp
ct ty
or
C
C
R
5
C
XC
R
6
G
PR
15

**

B
.
% infection at 7 dpi

PJ

AGM PBMC Blocking Day 7 WIDE

0

**

*

**

100

**

80
60
40
20

M
C VC
XC a
L1 nd
6

L1
6
XC

M

VC

C

N

o

dr

ug

0

Figure 2.4: Blocking entry through CXCR6 limits SIVagmSab92018ivTF replication in sabaeus
lymphocytes. A) 293T cells were transfected with plasmids encoding sabaeus CD4-31 and one of the
following: sabaeus CCR5, CXCR6, GPR15, GPR1, APJ or empty vector. Cells were treated with 15uM
maraviroc, 500ng/mL human CXCL16 or vehicle alone for one hour and then infected with the luciferase
reporter pseudotype containing the SIVagmSab 92018ivTF Env. Cells were lysed 72 hours post-infection
and luciferase content was read by measuring relative light units (RLU). Infections were carried out in
triplicate and data (means ± standard deviation) are representative of 3 replicate experiments. B) Sabaeus
PBMC were stimulated for 3 days with 5ug/mL PHA and 100U/mL IL-2, then treated with vehicle alone,
15uM maraviroc, 500ng/mL human CXCL16 or both blocking agents for one hour. Cells were then infected
in duplicate with SIVagmSab92018ivTF generated from an infectious molecular clone. Infection was
measured by p27 production in supernatant at day 7, and shown for each treatment as a percent of vehicle
alone (no drug). Each symbol represents data from a different animal’s PBMC, and shown are median and
standard deviation values for each condition. *, P<0.05; **, P< 0.01 (two-tailed paired t-test). (Figure
originally printed in Wetzel et al, JVI 2017.)
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Discussion
In contrast to HIV-1 and SIVmac-infected nonprogressors that avoid pathogenesis mainly by
controlling viremia, natural hosts do not experience disease while maintaining high viral loads,
which is likely the result of prolonged coevolution with their SIVs. Recent evidence suggests that
one mechanism for this benign coexistence is linked to patterns cell targeting within such hosts
(130). Since cell targeting is determined largely by entry, in this study I aimed to identify entry
pathways used by the natural host virus SIVagmSab.

I found that CXCR6 was used as a

coreceptor, in addition to CCR5, by diverse SIVagmSab Envs, including those isolated from wild,
naturally infected animals. GPR15 was also used, albeit less efficiently. Robust CXCR6 use
occurred at both high and low CD4 levels. Blocking CXCR6 inhibited SIVagmSab replication in
PBMC, confirming that it not only functions in vitro, but also mediates infection of primary target
cells relevant to infection in vivo.

In vitro use of alternative coreceptors by various SIVs was first observed years ago, and many
studies used human, not species-matched molecules (96-98). However, CCR5 was long thought
to be the only coreceptor relevant in vivo. One initial exception was SIVrcm that infects the
natural host red-capped mangabeys (RCM).

Many RCM are CCR5-null due to a common

deletion allele, yet SIVrcm was found to use CXCR6 and CCR2b, and not CCR5, to enter cells
(99, 100). More recently, our lab identified a common CCR5 deletion allele in sooty mangabeys
(SM) (104); we found that homozygous, CCR5-null animals were infected at a similar frequency
to wild-type CCR5 SM and maintained nearly equivalent viral loads. These data demonstrate a
lack of CCR5-dependence of SIVsmm, and later studies identified CXCR6 as an additional
coreceptor for SIVsmm isolated from both wild type CCR5 and CCR5-null SM (105, 107). A lack
of CCR5-dependence was also observed for the natural host virus SIVagmVer, as blocking entry
through CCR5 did not hinder replication in vervet PBMC (116). Alongside these data
demonstrating non-CCR5 pathway use by SIVsmm and SIVagmVer, this study bolsters a
paradigm of alternative coreceptor usage by natural host viruses. This provides a stark contrast to
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pathogenic SIVmac infection of macaques and HIV-1 infections of humans, which is largely
restricted to use of CCR5 as a coreceptor (89-91, 107, 116, 131, 132).

Natural hosts species, including African green monkeys, are characterized by a low frequency of
CCR5+ CD4+ T cells, and reduced expression of CCR5 on critical CD4+ T cell subsets has been
implicated as a mechanism by which such subsets are protected from infection (67, 72, 73).
However, this observation also raised the question as to how natural hosts are able to sustain
high viral loads with a reduced pool of target cells. The identification of CXCR6 as an additional
coreceptor for SIVagmSab (and SIVsmm) may answer this question, as CD4+ T cells that lack
CCR5 but express CXCR6 (or other alternative coreceptors) would be target cells that were
previously unappreciated.

The use of alternative coreceptors in CCR5-low natural hosts likely also contributes to distinct
outcomes of infection as compared to the CCR5-dependent infection of non-natural hosts. Unique
features of natural host infection that contribute to the lack of pathogenesis include resolution of
immune activation after acute infection, lack of microbial translocation, maintenance of gut
immunity and integrity, reduced lymph node infection and inflammation and a maintenance of
peripheral CD4+ T cells (112, 113). One identified mechanism that contributes to these distinct
features is divergent cell targeting by natural host SIVs. While both natural and non-natural SIVs
replicate in cells that turnover quickly, central memory (Tcm) and stem cell memory (Tscm) CD4+
T cells are relatively spared from infection in sooty mangabeys, but not rhesus macaques (72,
73). This preservation likely supports the maintenance of CD4+ T cell homeostasis in natural
hosts. In lymph nodes, T follicular helper cells (Tfh) that participate in germinal center reactions
are infected at a lower frequency in natural hosts than non-natural hosts, likely contributing the
absence of inflammation and fibrosis in this compartment (56). In the gut, the SIV infection status
of Th17 cells in the gut of natural hosts has not been characterized, but Th17 cells are maintained
in SIV infection of SM and AGM (77). In SIVmac infection of RM and HIV-1 infection in humans,
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Th17 cells are lost, which is associated with the disruption of barrier integrity, microbial
translocation and chronic immune activation (77-79). Thus, expression of these alternative
coreceptors such as CXCR6 is likely restricted on and within these critical, relatively protected
CD4+ subsets and tissues, and instead found on more expendable CD4+ cells.

To accurately define targets cells of SIV, it will be critical to determine CXCR6 expression
patterns of CD4+ cells in natural hosts. CXCR6 is thought to be an extralymphoid homing
receptor, contributing to adhesion in the periphery via interactions with its ligand CXCL16 (133135). In humans, enrichment of CXCR6+ cells is common at sites of inflammation, and CXCR6
expression has been described mainly on memory CD4+ T cells, although expression on naïve
cells has also been reported (136-139). Studies of CXCR6 surface expression on nonhuman
primate cells have not been performed due to a lack of cross-reactive reagents.

Recently,

Riddick et al measured CXCR6 mRNA in vervet AGM CD4+ T cells and found expression in both
naïve and memory CD4+ T cell subsets (116). However, to accurately identify natural host SIV
target cells, it will be necessary to define CXCR6 surface expression on CD4+ cells in these
animals. Such CXCR6+CD4+ T cells likely support viremia, while CD4+ T cells that lack CXCR6
(and CCR5) are protected from infection and able to maintain immune system function.

Blocking entry through CCR5 and CXCR6 using MVC and CXCL16, respectively, was not
sufficient to completely inhibit replication of SIVagmSab92018ivTF in sabaeus lymphocytes. This
may be due to incompletely blocking of these pathways by maraviroc and CXCL16 (Figure 2.4A),
but SIVagmSab could also use additional coreceptors. Of the coreceptors tested, GPR15 is the
most likely candidate as it is used nearly as efficiently as CCR5 and CXCR6 (Figure 2.3) and is
expressed on human CD4+ T cells (140). Interestingly, SIVmac, the descendent of SIVsmm, is
able to use RM GPR15 in an in vitro transfection system (107). However, use of GPR15 ex vivo
has not been observed, as blocking CCR5 is sufficient to inhibit replication in RM PBMC (107,
116), and concordant results have been described in vivo (141). Therefore, use of GPR15 in vitro
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may not reflect use in vivo and must be tested directly. In this study, I was unable to block entry
through GPR15 as its ligand has not been identified and no small molecule against this receptor
is available. Future studies using GPR15 knockdown or deletion approaches in sabaeus PBMC
would address its use. It is unlikely that GPR1 and APJ permit entry of SIVagmSab in sabaeus
PBMC, as their use in vitro was minimal and studies of humans and rodents do not describe
expression on relevant CD4+ target cells (142-146). Lastly, while the panel of coreceptors tested
here encompassed the major non-CCR5 coreceptors for HIV and SIV described to date, it is
possible that entry is permitted by a currently unknown 7TMR.

The sabaeus AGM whose cells were included in this study were polymorphic for CCR5,
concordant with previous observations, and several animals were heterozygous for a
polymorphism that has been shown to limit SIVagm replication in vitro (93R) (98, 129). However,
no obvious replication defect was observed in PBMC from these animals. Also, AGM maintain a
low frequency of CCR5+CD4+ T cells (98, 101). Together, these observations suggest a long
history of coevolution between SIVagm and its host, driven by deleterious consequences of
CCR5-mediated infection.

In contrast, all CXCR6 alleles sequenced here were identical,

suggesting distinct evolutionary pressures have been exerted on these two coreceptors.

I

speculate that the lack of AGM CXCR6 diversity despite prolonged AGM/SIVagm coexistence
reflects a benign outcome when CXCR6 is used to enter target cells.

Use of non-CCR5 pathways has now been observed for three distinct natural host viruses,
SIVagmVer, SIVsmm, and SIVagmSab, and CXCR6 use in lymphocyte infection has been
confirmed for the latter two. Importantly, these viruses are quite diverse; SIVagm and SIVsmm
represent two distinct SIV lineages and molecular clock analyses combined with biogeographic
calibration place their most recent common ancestor to over 100,000 years ago (36, 38).
Furthermore, SIVagmSab and SIVagmVer infect nonsympatric subspecies of African green
monkeys in West and East/Southern Africa, respectively, and also diverged over 100,000 years
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ago (36). Despite this distance, use of non-CCR5 entry pathways is a common feature among
these viruses. This suggests that use of such pathways is the norm among natural host SIVs that
have coevolved with their hosts. In contrast, restriction to CCR5 use only occurs in more recent
or zoonotic infections, such as SIVmac or HIV-1. In these newer hosts, CCR5+ CD4+ cells are
abundant, perhaps due to lack of evolution with CCR5-using viruses, and immunodeficiency
ultimately develops. It is not clear why CXCR6 use might be lost, and virus thus restricted to
CCR5, but may be linked to factors required to overcome cross-species transmission barriers.
For SIVmac, which is the product of cross species transmission of SIVsmm into macaques, the
source of the restriction is known; RM CXCR6 encodes a polymorphism in the N terminus of
CXCR6, S31R, which renders it a poor coreceptor (106). For HIV-1, features of Env prevent
CXCR6 use, although rare CXCR6-using isolates have been reported (97, 147). To determine
changes that may have occurred in coreceptor usage in the emergence of HIV-1, it will be
necessary to define the coreceptor usage patterns of SIVgsn/mus/mon, the natural host
forerunner of env of SIVcpz, which gave rise to HIV-1 (39, 41, 45, 148).

In summary, this study supports a model of SIV/HIV tropism where in non-natural hosts, an
abundance of CCR5+ cells results in the infection and disruption of many CD4+ T cell subsets
and tissues and leads to immunodeficiency. In contrast, in natural host infection, where CCR5+
cells are infrequent, use of CXCR6 (and possible other coreceptors) directs SIV towards cells that
are able to support viremia without immunodeficiency. Defining CXCR6+ cells, both in blood and
tissues will be essential to understanding natural host cell targeting.
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Materials and Methods
Sabaeus African green monkey PBMC
PBMC from sabaeus AGM (from a Caribbean- born colony) were isolated from whole blood as
previously described (101), cryopreserved and thawed before use. Animals were housed at the
University of Pittsburgh in accordance with the Guide for the Care and Use of Laboratory Animals
(149), the Association for Assessment and Accreditation of Laboratory Animal Care, and the
Animal Welfare Act. Animal procedures were approved by the IACUC of the University of
Pittsburgh.

Cloning of sabaeus CD4 and coreceptor molecules
Genomic DNA was isolated from resting sabaeus AGM PBMC (n=1, AGM 30) using the QIAamp
DNA Blood Mini Kit (Qiagen) and RNA was isolated from both resting and concanavalin A
(ConA)/IL-2 stimulated PBMC (n=2, AGM 30 and AGM 31) using the RNeasy Plus Kit, (Qiagen).
cDNA was synthesized using the Superscript III First Strand Kit (Invitrogen) using random
hexamers (for CD4), oligodT (for CXCR4) or gene-specific primers (for CCR2b and CCR4).
Primers for 7TMR cDNA synthesis and PCR amplification were previously described (28) as were
the CD4 primers (AGM CD4 for2 and AGM CD4 rev) (29). Sabaeus CD4 and full-length 7TMRs
were amplified from genomic DNA (APJ, CCR3, CCR5, CCR8, CXCR6, GPR1, GPR15) or cDNA
(CD4, CCR2b, CCR4, and CXCR4) using Phusion High Fidelity DNA polymerase (New England
BioLabs). Coreceptors were amplified from AGM 30. Reactions included 50ng gDNA or 2uL
cDNA synthesis reaction, and cycling conditions followed kit protocol as previously reported
(105), but annealing temperatures were modified as follows: 64°C (APJ, CCR3, CCR4, CCR8,
CXCR6, GPR1, GPR15, CXCR4) 60°C (CCR2b) 61°C (CCR5) or 72°C (CD4). Amplified genes
were ligated into pcDNA3.1+ using dual restriction enzyme digest (CCR2b, CCR3, CCR4, CCR8
or CXCR6), or into the pcDNA3.1D/V5-His-TOPO vector by TOPO Directional cloning (CD4, APJ,
GPR1, CCR5, CXCR4 or GPR15) using the pcDNA3.1 Directional TOPO Expression Kit
(Invitrogen). Clones were screened by restriction digest analysis and confirmed by Sanger
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nucleotide sequencing. Nucleotide and amino acid alignments were performed using the
ClustalW algorithm in MacVector 13.5.2. 7TMR membrane topology predictions
using

TMpred

were

made

(http://www.ch.embnet.org /software/TMPRED_form.html). Expression of

coreceptor molecules was ensured by measuring entry into target cells by previously described
promiscuous SIVsmm pseudotypes (27) or by flow cytometry (CCR2b, CCR4).

Cloning of SIVagmSab envelopes
Plasma samples were collected in Senegal from sabaeus AGM (89042 and 89044) that were
SIV+ upon capture, and stored at the Institut Pasteur. Viral RNA was isolated from plasma
samples using Viral RNA Mini Kit (Qiagen) and cDNA was synthesized using Superscript III
reagents and a gene-specific primer (5’-CTCCWCCCTGGAAAGTCCCKCT-3’) modified from a
previously reported primer (119). SIVagmSab Envs were amplified in 50uL PCR reactions using
Platinum Taq DNA Polymerase High Fidelity (Invitrogen) and forward
(5’ CACCCCSCTCCAGGCCTGTRNCAATA-3’) and reverse (5’-CCARCCATCSACWATDCCCC3’) primers designed from published SIVagmSab sequences using Primer3 (150), with the bases
required for TOPO Directional cloning in bold. . 3kb amplicons were cloned into pcDNA3.1D/V5His-TOPO using the pcDNA3.1 Directional TOPO Expression Kit (Invitrogen). Clones were
screened by colony PCR, and successfully ligated clones were tested for function on transfected
293T cells expressing sabaeus CD4 and CCR5 or CXCR6.

SIVagmSab Env sequencing and phylogenetic analyses
SIVagmSab envelopes 89042 and 89044 were sequenced using a MiSeq sequencer (Illumina)
and reads were aligned using Geneious 7.1.7 software (Biomatters Ltd). A maximum likelihood
phylogenetic tree was generated using only the overlapping portion (1882 bp) of previously
published SIVagm sequences and the two novel envs. Sequences were first aligned using
MAFFT (35) and jModelTest (36) was used to determine the best-fit substitution model. The
phylogenetic tree was generated with PhyML v3.0 (37, 38) using the General Time Reversible
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(GTR) substitution model and concordantly estimating the proportion of variable sites and the
gamma distribution parameter from the sequence data and the phylogeny. 1000 bootstrap
replicates were performed. Figtree v1.4.2 was used to visualize the tree, which is rooted at the
midpoint (http://tree.bio.ed.ac.uk/software/figtree/). The scale bar represents 0.2 nucleotide
substitutions per site.

Coreceptor functional analyses using pseudotyped virus
Pseudotype reporter viruses were generated by transfecting 293T cells with an SIVagmSab Env
plasmid and a backbone pNL43-Luc-E-R+ plasmid using Fugene 6 transfection reagent
(Promega) as previously described (105). The following day, cells were washed with PBS and
fresh supplemented DMEM was added. 48 hours later, supernatant was collected and spun with
5% sucrose to pellet cell debris. p24 ELISA was performed on all stocks to allow normalization
for infections.

HEK 293T cells were maintained in Dulbecco’s modified Eagle medium supplemented with
10%FBS, 1% L-glutamine and 1% penicillin/streptomycin. 2.5e5 293T cells/ well were plated in
12-well plates and transfected with 250ng CD4 and 250ug coreceptor/empty pcDNA3.1+ (except
where otherwise noted) using Fugene 6 reagent. The following day, cells were lifted, washed and
replated at 2e4 cells/well in 100uL/well in 96-well plates. The following day, SIVagmSab Env
pseudotypes were incubated with 50 units/mL DNase (Roche) for 15 minutes, and pseudotypes
normalized by p24 amount were added/well. Amount of virus/well varied slightly between
experiments, as follows: CD4 comparison, (Fig 1) 34ng; Env comparison and titration
experiments (Figs. 2B, 3) 10ng; Coreceptor blocking (Fig. 4A) 4ng. Plates were spinoculated for
2 hours at 1200g and incubated for 72 hours at 37°C 5% CO2. To measure entry, cells were
lysed with 50uL 0.5% Triton X in PBS, and luciferase content read by adding 50uL luciferase
reagent (Luciferase Assay System, Promega) and reading RLU on a Luminoskan Ascent
(Thermo Labsystems). For all experiments, target cells were infected in parallel with pseudotypes
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expressing the vesicular stomatitis virus glycoprotein (VSVg) to ensure differences in entry were
coreceptor specific.

To confirm that equivalent amounts of the coreceptor plasmid yielded similar levels of expression,
and that titration experiments resulted in similar decreases in expression levels for different
coreceptors, 293T cells were transfected with human CCR5, CXCR6, and GPR15 and stained by
FACS analysis using anti-human coreceptor antibodies 3A9 (CCR5; BD Pharmingen), K041E5
(CXCR6; BioLegend), and 367902 (GPR15; R&D Systems). Validation of AGM CD4 plasmid
titration experiments was done similarly, using antibody L200 (BD Pharmingen).

To test the function and specificity of coreceptor blocking agents, transfected target cells were
pretreated for one hour at 37°C with the following treatments (values represent final
concentration): No drug (PBS and DMSO), 15uM maraviroc (in DMSO, with PBS added) (NIH
AIDS Reagent Program) 500ng/mL human recombinant CXCL16 (in PBS, with DMSO added)
(R&D Systems) and both maraviroc and CXCL16.

Sabaeus PBMC infection
Cryopreserved sabaeus PBMCs were thawed and stimulated with 5ug/mL PHA-P (Sigma) in
RPMI

Medium

1640

supplemented

with

10%

FBS,

1%

L-glutamine

and

1%

penicillin/streptomycin. 100U/mL IL-2 was added the following day. After 72 hours of stimulation,
2e5 cells/well were plated in a 96-well round bottom plate in duplicate and incubated for one hour
at 37°C with the following treatments (values represent final concentration): No drug (PBS and
DMSO), 15uM maraviroc (in DMSO, with PBS added), 500ng/mL human recombinant CXCL16
(in PBS, with DMSO added) and both maraviroc and CXCL16. Treatments occurred in complete
RPMI supplemented with 100U/mL IL-2.

Following incubation, 5ng p27 SIVagmSab 92018ivTF

was added and cells were spinoculated at 1200g for 90 minutes, then incubated at 37°C/5%CO2
overnight. The following morning, cells were lifted and washed two times in complete RPMI, and

54

the final wash was collected for Day 0 measurement. Cells were resuspended in 200uL complete
RPMI plus 100U/mL IL-2 and appropriate treatment, and 100uL (50%) supernatant was collected
and replaced with IL-2/treatment media on days 3, 7, 10, and 14. Virus replication was measured
by p27 Gag ELISA (Perkin-Elmer). For infections lacking blocking agents, p27 values at day 7
ranged from 5000-16000pg/mL.

Accession numbers. Sabaeus AGM CD4 and coreceptor sequences cloned here were
deposited in GenBank under accession numbers KY225904 to KY225915. SIVagmSab env
sequences were deposited in GenBank under accession numbers KY225916 and KY225917.
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CHAPTER 3

CXCR6 Use by SIVmus, but not SIVcpz, Suggests Coreceptor
Bottleneck Occurred in HIV-1 Emergence
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Abstract
HIV-1 originated from the cross-species transmission of SIVcpz, which infects chimpanzees, into
humans. SIVcpz is the product of a recombination event between two viruses that crossed the
species barrier, with a virus of the SIVgsn/mus/mon lineage contributing the envelope gene (env).
SIVgsn/mus/mon infects greater spot-nosed monkeys, mustached monkeys and mona monkeys,
respectively, which are considered “natural hosts” of these species-specific SIVs. While these
species have not been studied in detail, SIV-infected natural hosts in general maintain high viral
loads but do not progress to AIDS. In contrast, SIVcpz is pathogenic in its host, like HIV-1 in
humans. Recent studies from our lab and others have indicated that use of the entry coreceptor
CXCR6 in addition to CCR5 is a common feature of natural host SIVs, including SIVsmm that
infects sooty mangabeys and SIVagm that infects African green monkeys. However, the use of
species-matched coreceptors by SIVcpz and SIVgsn/mus/mon are not known. In this study, I
defined the coreceptor usage patterns of the two HIV-1 env forerunners. I found that SIVcpz was
restricted to use of species-matched CCR5 for entry, like HIV-1 in humans, whereas SIVmus was
able to use both CCR5 and CXCR6, like other natural host viruses. Coreceptor use was
determined by Env, not coreceptor sequence, with a V3 loop Pro residue contributing to CCR5
restriction. These data bolster the finding that CXCR6 use is common among natural host
viruses, extending it to the natural host forerunners of the HIV-1/SIVcpz lineage, and show that
use thereof can be lost upon cross-species transmission.

This coreceptor bottleneck in

chimpanzees may have altered cellular targeting, thereby disrupting the equilibrium between virus
and host observed in natural host infections and instead promoting pathogenicity.
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Introduction
HIV-1, the virus that causes AIDS, originated from the cross-species transmission of the simian
immunodeficiency virus (SIV) that infects chimpanzees (Pan troglodytes), SIVcpz, into humans
(1, 2). SIVcpz is the product of the recombination of two SIVs that crossed the species barrier
from their natural hosts into chimpanzees: SIVrcm that infects red-capped mangabeys (RCM,
Cercocebus torquatus) and an SIV of the lineage SIVgsn/mus/mon which infects greater spotnosed monkeys (GSN, Cercopithecus nictitans), mustached monkeys (MUS, Cercopithecus
cephus) and mona monkeys (MON, Cercopithecus mona), respectively (3-5). The 5’ half of
SIVcpz, which encodes gag and pol, is derived from SIVrcm, while the 3’ half of SIVcpz, which
encodes env, is derived from SIVgsn/mus/mon. RCM, GSN, MUS and MON are termed natural
hosts of SIV, as they are infected with species-specific strains of virus, but are not thought to
progress to immunodeficiency, akin to the well-studied natural hosts sooty mangabeys (SM,
Cercocebus atys) and African green monkeys (AGM, Chlorocebus spp.) (6, 7). This lack of
pathogenicity is thought to be the product of many years of virus-host coevolution, and contrasts
with “non-natural” HIV-1 infection in humans that leads to AIDS without treatment, as well as
SIVcpz infection of chimpanzees, where less severe but clear pathology has been observed in
the wild (7, 8).

Like non-natural hosts, infected natural hosts maintain high viral loads and frequent turnover of
infected cells, demonstrating that lack of disease progression is not due to control of the virus (911). Despite high viral loads, natural hosts do not endure many of the features of pathogenic
infection observed in infected humans and SIVmac-infected rhesus macaques (RM, Macaca
mulatta), the animal model for HIV-1 infection, such as widespread loss of virus target CD4+ T
cells, lymph node inflammation and fibrosis, gut barrier breakdown and microbial translocation,
and chronic immune activation (12). Instead, CD4+ T cell loss is limited to the gut and recovers,
lymph node structure and function is maintained, gut integrity is preserved, and immune
activation resolves after acute infection (6, 13). One mechanism implicated in the lack of disease
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progression is limited infection and/or loss of certain critical CD4+ T cells, which preserves
immune function. Such critical CD4+ T cell subsets include central memory (Tcm) and stem-cell
memory (Tscm) CD4+ T cells, which maintain memory CD4+ T cell homeostasis, T follicular
helper cells (Tfh) that reside in lymphoid tissues and provide B cell help, and Th17 cells, which
maintain the gut barrier and immune functions (14-17). This subset protection from infection and
loss likely allows natural hosts to avoid immunopathology despite infection of immune system
cells, and clearly suggests that to understand pathogenesis, we must first understand the
determinants of SIV cellular targeting in natural hosts, and how they may have changed as HIV-1
emerged from several cross-species transmission events.

HIV and SIV target cells are largely defined by expression of the receptor CD4, and a 7
transmembrane G protein coupled receptor (7TMR) coreceptor, both of which are engaged by the
Env glycoprotein to permit entry. HIV-1 enters cells using the chemokine receptor CCR5 as a
coreceptor, which is required for human infection (18-20), although HIV-1 sometimes evolves
later to use CXCR4 in addition to or instead of CCR5 (21, 22). SIVs use CCR5 for entry, but very
rarely use CXCR4 (23-25). While it was long known that SIV can enter cells using additional
7TMRs in vitro, including CXCR6 and GPR15, these studies often used coreceptors of human
origin, and accepted dogma was that CCR5 was the sole coreceptor used by SIVs (26-28).
Studies of several natural host species have revealed that natural hosts CD4+ T cells infrequently
express CCR5, possibly as a mechanism to protect CD4+ T cells from SIV infection (29).
However, this raised the question as to how natural hosts are able to maintain such high viral
loads with limited target cells and rapid turnover of infected cells.

One exception to the established dogma was SIVrcm that infects the natural host red-capped
mangabey (RCM). RCM are frequently CCR5-null due to a common deletion allele, and SIVrcm
cannot use CCR5 for entry, but instead enters cells via CXCR6 and CCR2b. More recently, our
lab identified a CCR5 deletion allele that is common among sooty mangabeys at Yerkes National
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Primate Research Center, which also rendered homozygous animals CCR5-null. Despite lacking
CCR5 on the cell surface, these animals were infected with SIVsmm at a similar frequency to wild
type animals and were able to maintain high viral loads, indicating that CCR5 is not necessary for
infection of sooty mangabeys. Further investigation determined that CXCR6 permits SIVsmm
entry in addition to CCR5, as studies showed robust use of CXCR6 of SM origin by SIVsmm in
vitro, and blocking use of CXCR6 with its ligand CXCL16 limited SIVsmm replication in SM
lymphocytes (30, 31). Our study of a second natural host, AGM of the subtype sabaeus, revealed
that sabaeus CXCR6 is a robust coreceptor for SIVagmSab in vitro, and like in SM, blocking use
of CXCR6 via CXCL16 treatment limited replication in sabaeus lymphocytes (Chapter 2) (32). In
vitro use of species-matched CXCR6 was found in a third natural host, AGM of the subtype
vervet (33). Therefore, CXCR6 use (in addition to CCR5 use) appears to be a common feature of
viruses that infect CCR5-low natural hosts.

As mentioned above, the SIV that gave rise to env of pathogenic SIVcpz and HIV-1 is the natural
host virus SIVgsn/mus/mon.

However, it is not known if SIVgsn/mus/mon can use species-

matched CXCR6 for entry like other natural host viruses. Furthermore, the ability of SIVcpz to
use species-matched coreceptors in addition to CCR5 is also unknown. Therefore, in this study, I
tested the ability of SIVmus and SIVcpz to use species-matched CCR5, CXCR6, GPR15, and
CXCR4 in vitro. I found that like HIV-1, SIVcpz was restricted to use of CCR5 for entry. In
contrast, SIVmus was able to enter cells using species-matched CXCR6 in addition to CCR5, and
experiments where species coreceptors were swapped indicated that CXCR6 use was
determined by Env. Surprisingly, SIVmus was unable to enter cells expressing chimpanzee CD4.
I also compared these closely related viruses to probe Env determinants of coreceptor usage and
found that residue 326P, located in the V3 loop of SIVcpz and HIV-1 Env, is incompatible with
CXCR6 use. Together, these data demonstrate that CXCR6 use is a feature of the natural host
virus SIVmus, and that loss of use of this coreceptor coincided with the development of
pathogenesis as the virus transmitted between hosts to give rise to SIVcpz, and then HIV-1.
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Results
Cloning and analysis of candidate coreceptors and CD4 from chimpanzee, mustached
monkey and greater spot-nosed monkey
I first aimed to define coreceptor usage patterns of HIV-1 ancestors SIVcpz and
SIVgsn/mus/mon. Given that single amino acid changes can alter coreceptor functionality (34), it
is necessary to test SIVcpz and SIVgsn/mus/mon on species-matched candidate 7TMR and CD4
to accurately identify virus coreceptors. I focused the analysis on CXCR6, a robust coreceptor for
several natural host SIVs, GPR15, a more moderate natural host SIV receptor, and CXCR4,
which is used by certain HIV-1 isolates but not SIVs, in addition to the canonical coreceptor
CCR5 (30-32).

I amplified cpzCCR5, cpzCXCR6, cpzGPR15 and cpzCXCR4 from genomic DNA or cDNA from
one Pan troglodytes verus chimpanzee using primers that lie outside the open reading frame
(ORF) of each gene (30), and cloned each into an expression vector. I cloned the candidate
coreceptors from the P.t. verus subspecies of chimpanzee because they are housed at Yerkes
National Primate Research Center and the stored samples were readily available; however, P.t.
verus are not infected with SIVcpz in the wild like the subspecies P.t. troglodytes or P.t.
schweinfurthii (2, 35). Therefore, I asked whether the cloned P.t. verus coreceptors were indeed
representative of the latter two subspecies. The cloned P.t. verus coreceptor genes were
sequenced and aligned to published deep sequencing data from four P.t. troglodytes and six P.t.
schweinfurthii chimpanzees (data not shown) (36). The cpzCCR5 and cpzCXCR4 clones were
also compared to published P.t. troglodytes alleles (37). This analysis revealed that the P.t. verus.
candidate coreceptors represented alleles of the P.t. troglodytes and P.t. schweinfurthii at the
amino acid level; I identified at least 1 synonymous SNPs between the chimpanzee subspecies
per coreceptor, but only one nonsynonymous SNP, which occurred in GPR15. Two P.t.
troglodytes chimpanzees were heterozygous for GPR15, with one allele matching the P.t. verus
clone by encoding S275, while the other encoded P275; this residue lies in the third extracellular
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loop (ECL3). Also, the CXCR6 and GPR15 amino acid sequences cloned here match previously
published chimpanzee alleles (subspecies unknown) (38). In summary, the P.t. verus candidate
coreceptor genes cloned here also reflect P.t. troglodytes and P.t. schweinfurthii coreceptors, and
are thus appropriate for SIVcpz analysis. For cpzCCR5 and cpzCXCR6, the sequences of the Nterminus and second extracellular loop (ECL2), the domains likely involved in coreceptor-Env
interactions based on studies of HIV-1 and human coreceptors (39), are shown in Figure 3.1.

The env gene of SIVcpz is derived from a member of the lineage SIVgsn/mus/mon. Available
biological samples of these species are limited to stored gDNA extracted from rare bushmeat
samples (5, 40, 41). Therefore, I focused on MUS and GSN for analysis because we were able to
obtain bushmeat specimens from these species.

Coreceptors of interest that are encoded by a single exon (CCR5, CXCR6 and GPR15) were
cloned from MUS 1085 and GSN 1365 using previously described primers (30).

To clone

CXCR4, which has two exons, both exons were amplified individually and spliced together via
PCR as described in Methods.

Clones were sequenced and when possible, compared to

previously described MUS and GSN protein sequences. musCCR5 was different from the one
previously sequenced allele by encoding a Pro at position 35 instead of a Leu (42). gsnCCR5 is
polymorphic, and the molecule cloned here matches several previously described alleles at the
amino acid level (42). No sequences for mus or gsnCXCR6, GPR15 or CXCR4 have been
previously reported. musCXCR6 and gsnCXCR6 were nearly identical, but musCXCR6 encoded
Arg at position 31, which is the same amino acid that renders rmCXCR6 a poor coreceptor for
SIVmac (34). In contrast, gsnCXCR6 encoded the more common Ser residue at position 31 that
is associated with robust coreceptor function. The alignment of the N-terminus and ECL2 of mus
and gsnCCR5 and CXCR6 with those of human and chimpanzee are shown in Figure 3.1. The Ntermini of mus and gsnCXCR6 are quite distinct from the N-termini of the human and chimpanzee
molecules, differing in identity by at least five residues.
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To generate musCD4 and gsnCD4, I amplified and sequenced the nine CD4 exons from gDNA
from two MUS (1085 and 1246) and two GSN (42 and 1289), and musCD4 and gsnCD4 were
then synthesized and inserted into expression vectors. Both musCD4 and gsnCD4 differed from
human CD4 at 16 of 109 amino acid residues in domain 1, which interacts with the SIV/HIV Env
(43). Chimpanzee CD4 has been cloned previously and was provided by B. Hahn and F. BibolletRuche (44). cpzCD4 differs from human CD4 at three residues in this domain. Overall, the
differences in CD4 sequence, as well as coreceptor sequence, underscore the importance of
testing coreceptor usage of viruses on their species-matched molecules.

SIVcpz is restricted to use of cpzCCR5 for entry, while SIVmus can enter using musCXCR6
as well as musCCR5
To test coreceptor usage of SIVcpz, expression vectors containing cpzCD4 and each CPZ
candidate coreceptor were transfected into CF2th-Luc cells that contain a Tat-driven luciferase
reporter. Cells were then infected with SIVcpz derived from four diverse infectious molecular
clones: SIVcpzPts BF1167, isolated from P.t. schweinfurthii, or SIVcpzPtt EK505, MB897, or
MT145, all isolated from P.t. troglodytes. Virus entry was quantified by luciferase production
measured in relative light units. For all SIVcpz isolates tested, only cells expressing cpzCD4 and
cpzCCR5 permitted greater entry than cells transfected with cpzCD4 alone (Figure 3.2A, left
panel). To confirm expression of the candidate coreceptors from the expression plasmids, I
transfected 293T cells with these constructs, and infected them with a luciferase reporter virus
carrying an unusual promiscuous SIVsmm Env that can use multiple coreceptors for entry (Figure
2A, right panel)(30). I observed robust entry through all of these CPZ coreceptors, demonstrating
functional expression. Therefore, SIVcpz is similar to HIV-1 but unlike natural host SIVs, and is
restricted to use of species-matched CCR5 as a coreceptor and does not use CXCR6 or GPR15.
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Since no SIVmus or SIVgsn envelopes or infectious molecular clones have been isolated for use
in functional experiments to date, testing coreceptor usage first required amplification of
functional envs. I was able to amplify envs from gDNA from two SIVmus-infected MUS (1085 and
1246) (5, 40), and cloned these envs into expression vectors. Five envs (SIVmus1085) cloned
from MUS 1085 functioned robustly, while those from MUS 1246 (SIVmus1246) functioned only
very weakly (data not shown). I therefore proceeded to test coreceptor use of 3 envs amplified
from MUS 1085 (1-54, 4-1 and 4-12), which ranged from 96 to 98% amino acid identity to each
other and to the previously described SIV env sequence from this animal (5).

To test SIVmus1085 coreceptor use, 293T cells were transfected with expression plasmids
containing musCD4 and MUS coreceptor, or gsnCD4 and GSN coreceptor, and infected with
luciferase reporter pseudotypes carrying the SIVmus1085 Envs. In contrast to SIVcpz, SIVmus
was able to enter cells expressing species-matched CXCR6 in addition to CCR5; this was
observed for the species-matched MUS coreceptors as well as the closely related GSN
coreceptors (Figure 3.2B-C, left panels). The R31 residue that restricts entry of SIVmac through
rmCXCR6 did not restrict entry of SIVmus1085 through musCXCR6. Neither mus/gsnGPR15 nor
mus/gsnCXCR4 were used for entry. Robust entry of the previously mentioned promiscuous
SIVsmm (30) into target cells expressing all tested coreceptors demonstrates expression of these
molecules on the cell surface (Figure 3.2B-C, right panels). Therefore, SIVmus1085 enters cells
expressing species-matched CXCR6 and CCR5 (as well as gsnCXCR6 and gsnCCR5), like other
natural host viruses. In contrast SIVcpz only enters cells expressing species-matched CCR5, like
HIV-1. Since I observed consistent coreceptor use patterns among the all SIVcpz and SIVmus
strains tested, I performed further analysis with pseudotyped SIVcpzMT145 and SIVmus1085 154.
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Coreceptor usage pattern is determined by Env, not coreceptor species origin
The inability of SIVcpz to use cpzCXCR6 could be attributable to either the SIVcpz Env, or the
species origin (and thus amino acid sequence) of the CXCR6 molecule. Therefore, I first probed
coreceptor origin by testing the ability of SIVcpz to enter cells expressing musCD4 and
musCXCR6, which permitted SIVmus entry (Fig 1B). I transfected 293T cells with musCD4 along
with empty vector, musCCR5 or musCXCR6, or cpzCD4 along with empty vector, cpzCCR5 or
cpzCXCR6.

Cells were then infected with a luciferase reporter virus expressing the SIVcpz

MT145 Env. The SIVcpz MT145 pseudotype entered cells expressing CD4 and CCR5 from both
MUS and CPZ, but not those expressing CD4 and CXCR6 (Figure 3.3A). This result suggests
that the inability of SIVcpz to enter through CXCR6 is Env determined. To ask if cpzCXCR6
could function as a coreceptor for viruses in this lineage, I then infected 293T cells expressing
musCD4 and empty vector, musCCR5 or CXCR6, or cpzCCR5 or CXCR6, with reporter
pseudotypes expressing SIVmus1085. SIVmus1085 entered cells expressing musCD4 and each
of the coreceptors, although entry through cpzCXCR6 was the least robust (Figure 3B).
Together, these data suggest that the inability of SIVcpz to use CXCR6 is a property of Env, and
is not because of intrinsic poor coreceptor function of cpzCXCR6.

Finally, I tested the ability of SIVmus to enter cells expressing cpzCD4 and cpzCXCR6, in case
this combination of CD4 and coreceptor is not permissive to viruses of this lineage. Surprisingly,
while SIVmus1085 could enter cells expressing musCD4 and CPZ coreceptors, it could not enter
cells expressing cpzCD4 and CPZ coreceptors, as no entry above background RLU was
observed (Figure 3.4A). I then tested additional cpzCD4 alleles that vary at positions 52, 55 and
68, but found that none were able to permit entry (data not shown). This SIVmus entry defect
could be slightly rescued when human CD4, which varies from cpzCD4 by 4 total amino acid
residues, was used instead (Figure 3.4A).

In sharp contrast, SIVcpz exhibited no apparent

species CD4 preference, readily entering cells expressing musCD4, cpzCD4, or huCD4, in
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conjunction with cpzCCR5. Therefore, although SIVmus can enter cells via multiple coreceptors,
it strongly prefers species-matched CD4 to CPZ or human CD4.

SIVcpz V3 loop 326P is not compatible with CXCR6 use
Identifying distinct capabilities of CXCR6 use between the closely related SIVcpz and SIVmus
Envs provided a unique opportunity to probe Env determinants of CXCR6 usage. Given that the
V3 loop of Env is a key determinant of coreceptor usage in general (45), I aligned this region of
the Envs used in this study (Figure 3.5A, bold text) as well as additional published Envs in the
SIVgsn/mus/mon lineage (Figure 3.5A, plain text). I observed that residue 326 (SIVmac239
numbering), which falls in the crown of the V3 loop, encodes Pro for the SIVcpz strains, but Ala
for the members of the SIVgsn/mus/mon lineage. I then compared this residue across SIV and
HIV sequences for which the ability to use CXCR6 is known, and found that like SIVcpz, Pro was
typically encoded by HIV-1 isolates, among which CXCR6-using strains are very rare (46). In
contrast, no SIVs (or HIV-2) that can use CXCR6 encode Pro. Instead, Ala (SIVmus, SIVagm),
Thr (SIVrcm) or Ser (SIVsmm, SIVmac, HIV-2) is encoded at that position.

Based on these observations, I hypothesized that 326P restricts use of CXCR6. To test this, I
used site-directed mutagenesis to generate SIVmusA326P, which encodes Pro instead of the
native Ala at position 326, and the converse, SIVcpzP326A, which encodes Ala instead of Pro.
SIVmusA326P was unable to enter cells expressing musCD4 and musCXCR6, despite entering
cells expressing musCD4 and musCCR5, demonstrating that P326 is incompatible with CXCR6
usage (Figure 3.6A). In contrast, SIVcpz P326A was not able to enter cells expressing cpzCD4
and cpzCXCR6, or mus CD4 and mus CXCR6, indicating that 326A is not sufficient to confer
CXCR6 usage to SIVcpz.

I then asked if the entire SIVmus V3 loop was sufficient to confer CXCR6 use to SIVcpz, and
swapped the SIVmus 1085 1-54 V3 loop (Figure 5A) into the SIVcpz MT145 Env. The resulting
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virus was poorly infectious (entering cells at 4-5% of the RLU observed for the same amount of
wild type SIVcpz as measured by p24 capsid protein). Nevertheless, I did not observe rescue of
either musCXCR6 or cpzCXCR6 usage, suggesting that Env domains beyond the SIVmus V3
loop likely contribute to CXCR6 usage.
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Figure 3.1: Coreceptor and CD4 sequences vary in sequence between human, CPZ, GSN and MUS.
CCR5 and CXCR6 were cloned from CPZ, GSN and MUS genomic DNA. Sequences were aligned to the
human sequence, and shown are the N-terminus (N term) and the second extracellular loop (ECL2), the two
domains that interact with the virus glycoprotein (based on studies of human CCR5 and HIV-1 gp120). GSN
and MUS CD4 exons were sequenced from genomic DNA and aligned to known sequences of human CD4
and chimpanzee CD4; shown is domain 1 that interacts with HIV/SIV gp120. Residues identical to the
human sequence are represented as dots.
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Figure 3.2: SIVcpz is restricted to CPZ CCR5,
while SIVmus1085 can use MUS and GSN CCR5 and
2000
CXCR6 for entry. A) Left panel: CF2thLuc cells that contain a Tat-driven luciferase reporter were
1500
transfected with expression plasmids containing
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(No CoR). 48 hours later cells were infected1000
with one of four diverse SIVcpz isolates derived from infectious
molecular clones. Entry was quantified 48 hours
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CD4 and coreceptor of MUS (B) or GSN (C) origin, or empty vector (No CoR).
hours later cells were
SIVcpz 48
strain
infected with luciferase reporter viruses carrying SIVmus1085 Envs (left panel) or a promiscuous SIVsmm
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light units (RLU). A-D) Infections were carried out in triplicate and error bars represent one standard
deviation. One representative experiment is shown.
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Figure 3.4: SIVmus1085 cannot use chimpanzee CD4 for entry. 293T cells were transfected with
expression plasmids containing CD4 and coreceptor. The species origin of the CD4 and coreceptor are
indicated below the graph and abbreviated as M (mustached monkey) C (chimpanzee) H (human) or – for
no plasmid (coreceptor rows) or empty vector (CD4 rows). 48 hours post transfection, cells were infected
with luciferase reporter pseudotypes carrying the SIVmus1085 1-54 Env (A) or the SIVcpz MT145 Env (B).
Entry was quantified 72 hours later by lysing cells and measuring luciferase content by relative light units
(RLU). Infections were carried out in triplicate and error bars represent one standard deviation.
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Figure 3.5: Amino acid sequences of SIV and HIV V3 loops. A) The V3 loop amino acid sequences of
SIVcpz and SIVmus sequences used in this study (bold text) were aligned with other members of the
SIVgsn/mus/mon lineage (plain text) using the ClustalW algorithm. The V3 loop of the previously published
SIVmus-01CM1085 is identical to SIVmus1085 4-1 and 4-12. Residue 326 (SIVmac239 numbering) of the
V3 loop is boxed. Conserved residues are shaded in grey. B) The predominant amino acid residues that
occur at V3 crown residue 326 (SIVmac 239 numbering) or 313 (HIV HXB2 numbering) for SIVs and HIVs
where use of CXCR6 has been tested. *SIVmac can use other species’ CXCR6 for entry, but does not
efficiently enter through rmCXCR6 due to a S31R polymorphism in the N terminus of rmCXCR6.

78

Figure 4A: 20170406 point mutants V3 color by CoR
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Figure 3.6: SIVmus1085 Env determinants of CXCR6 usage: V3 loop residue 326P is not compatible
with CXCR6 usage, but neither 326A nor the SIVmus V3 loop is sufficient to confer CXCR6 usage. A)
SIVmus1085 1-54 and SIVcpz MT145 env constructs were mutated via site-directed mutagenesis to
generate V3 crown mutants SIVmusA326P and SIVcpzP326A. Luciferase reporter pseudotyped viruses
carrying these Envs, or SIVmus 1085 1-54 or SIVcpz MT145, were used to infect 293T cells expressing
musCD4 and coreceptor (M) or cpzCD4 and coreceptor (C). Entry was quantified 72 hours post-infection by
relative light units (RLU). B) The V3 loop of SIVcpz MT145 was replaced with the V3 loop of SIVmus1085 154 to generate SIVcpz-musV3. Pseudotypes carrying the SIVcpz-musV3 Env, or SIVmus1085 1-54 or
SIVcpz MT145, were used to infect 293T cells expressing musCD4 and coreceptor (M) or cpzCD4 and
coreceptor (C). Due to low infectivity of SIVcpz-musV3, entry was normalized to % entry through musCD4
and musCCR5 to enable comparison. Infections were carried out in triplicate and error bars represent one
standard deviation.
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Discussion
Humans in Africa continue to be exposed to SIV-infected African primates, largely due to
bushmeat hunting (41). Therefore, it is critical to understand the transmission events that lead to
the emergence of HIV-1 and its ancestor, SIVcpz. One of the earliest requirements for crossspecies transmission is entry into the cells of a novel host; therefore, I investigated coreceptor
usage of SIVcpz and its env ancestor SIVmus. Furthermore, studies from our lab and others have
linked use of the entry coreceptor CXCR6 (in addition to CCR5) to a benign disease course for
several natural host SIVs, while virus dependence on CCR5 (but not CXCR6) is associated with
progression to immunodeficiency. I hypothesized that as HIV-1 evolved from its natural host
ancestors and pathogenesis emerged, use of CXCR6 was lost.

In this study, I found that SIVcpz, which is pathogenic in its chimpanzee host, is restricted to use
of CCR5 like HIV-1 and the HIV-1 model SIVmac. In stark contrast, its natural host ancestor
SIVmus enters cells expressing CXCR6 as well as CCR5.

These coreceptor-use phenotypes

were determined by Env, not coreceptor origin, and I identified a Pro residue on the V3 crown of
SIV as a contributor to this restriction to CCR5 use. Lastly, SIVmus was unable to enter cells
expressing cpzCD4.

While SIVmus was able to use species-matched CXCR6 for entry, SIVcpz, the descendent of the
SIVgsn/mus/mon lineage, was restricted to use of CCR5, demonstrating that a coreceptor
bottleneck occurred with the emergence of SIVcpz. This pattern held for four diverse SIVcpz
isolates, including SIVcpzPtt (MT145, EK505 and MB897), the SIVcpz subspecies that crossed
into humans, and SIVcpzPts (BF1167), which has not crossed into humans (2, 35, 47).

SIVcpz was long thought to be nonpathogenic in chimpanzees, but this was largely due to
observations of very few SIVcpz-infected chimpanzees, as well as experimentally HIV-1-infected
chimpanzees (1, 48-51). However, a thorough non-invasive survey of habituated chimpanzees in
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West Africa revealed an increased death hazard and CD4+ T cell depletion among SIV+
chimpanzees when compared to their uninfected counterparts, indicating that SIVcpz is indeed
pathogenic for the two subspecies of chimpanzees in which it is found (8). While similar studies
have not been undertaken for MUS, GSN or MON monkeys, which are not held in captivity,
studies of SM, AGM and mandrills that have been long-infected with their species-specific SIVs
have led to the conclusion that SIV infections of African monkeys, like SIVmus of MUS, are likely
nonpathogenic (6, 7). Thus, the bottleneck from CCR5 and CXCR6 use by SIVmus to CCR5 use
by SIVcpz coincides with the emergence of pathogenesis within this virus lineage.

A parallel observation is made when comparing SIVsmm/SM and SIVmac/RM.

The cross-

species transmission of SIVsmm to RM occurred in the lab and not the wild, but the same
bottleneck is observed: natural host SIVsmm/SM infection uses CCR5 and CXCR6 (and possibly
other coreceptors) for entry, while pathogenic SIVmac/RM infection is restricted to CCR5 (31, 33,
52). Unlike SIVcpz, in the case of SIVmac, the cause for the bottleneck is coreceptor mediated,
as RM CXCR6 encodes an Arg residue in the N-terminus that renders it a poor coreceptor for
SIVmac (34). For the SIVmus-SIVcpz transition, where loss of CXCR6 use in SIVcpz is Env
determined, it is unclear why the cross-species transmission would result in loss of CXCR6 use in
SIVcpz emergence. Possible drivers include SIV Env adaptation to use chimpanzee CCR5 or
CD4, or chimpanzee immune system pressures, and these and others are discussed at length in
Chapter 5. While the mechanisms of restriction to CCR5 use are distinct for SIVmac and HIV-1,
macaques and humans both maintain a high frequency of CCR5+ CD4+ T cells (29), such that
use of this coreceptor for virus entry likely permits replication in cell types and anatomic
compartments that promote immunodeficiency.

A caveat of this bottleneck observation is that MUS and related monkeys are not well studied,
and as mentioned the lack of pathogenicity of these infections is presumed based on similarities
to the well-studied natural hosts like SM, AGM subspecies, and mandrills. Extensive bushmeat
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surveys have shown that SIV prevalence among MUS, GSN, and MON ranges from 0-7%, which
is much lower than the 50% prevalence observed among adult SM and AGM (7, 41, 53). This
low prevalence is closer to what is observed in more pathogenic infections, and some have
hypothesized that this may suggest a sub-optimal host-virus relationship (41). Furthermore, like
HIV-1 and SIVcpz, SIVgsn/mus/mon encodes vpu, which may be linked to the increased
pathogenicity of HIV compared to other immunodeficiency viruses (54). Therefore, surveys of
these monkeys in the wild, like those performed of sabaeus AGM (55, 56) and chimpanzees (8)
would be required to definitively confirm whether MUS, GSN and MON actually experience
nonpathogenic infection.

By identifying the distinct coreceptor usage patterns of the closely related SIVmus and SIVcpz, I
was able to probe determinants of CXCR6 use. I found that CXCR6 use in this lineage was
determined by the virus, not coreceptor sequence, and identified that a Pro residue at position
326/313 (SIVmac239/HIV HXB2 numbering), which is commonly found in the V3 loop of SIVcpz
and HIV-1, as incompatible with CXCR6 use in SIVmus. As shown in Figure 3.5B, no known
CXCR6-using virus encodes Pro at this position. Also, while experimental data on CXCR6 by
SIVs beyond those shown in Figure 3.5B are unknown, it is worth noting that no natural host SIVs
that have been sequenced to date encode a Pro at this position, such as SIVdrl that infects drills
(Mandrillus leucophaeus) and SIVsyk that infects Sykes’ monkeys (Cercopithecus albogularis),
suggesting a possible capacity for CXCR6 use (46). Interestingly, several rare HIV-1 isolates that
use CXCR6 in vitro code a Trp instead of a Pro at this position, although others retain the Pro
(27, 57). Given that neither the SIVcpz P326A nor the SIVcpz-musV3 mutant viruses were able to
use CXCR6 for entry, the data suggest that the requirements for CXCR6 use likely extend
beyond the V3 loop of Env. This finding is in agreement with a previous study that found that the
V1 and V2 domains, in addition to V3, were necessary to confer CXCR6 use from an SIV to HIV1 (58). However, given the low infectivity of the SIVcpz-musV3 mutant, I did not generate
additional mutants.
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Like other SIVs, SIVmus1085 did not enter cells expressing species-matched CXCR4. More
surprisingly, SIVmus1085 did not enter cells expressing species-matched GPR15. In vitro,
GPR15 is frequently used by SIVs, including SIVmac, SIVsmm and SIVagm, albeit with varying
degrees of efficiency (30, 32, 59). While I did not probe determinants of use of this coreceptor in
this study, others have identified a Pro at position 321 in the V3 loop as necessary for use of
GPR15 for SIVmac (60). This residue precedes the Pro that regulates CXCR6 use identified in
this study (326P) by five amino acids. While 321P is found in SIVsmm and SIVagm as well,
SIVmus1085 encodes Asn at this position, which may explain to the lack of GPR15 use observed
by SIVmus.

Differences in cell and tissue targeting between natural and non-natural HIV/SIVs are strongly
implicated in the distinct outcomes of infection. In non-natural host infections, critical memory
CD4+ T cell subsets such as Tcm, Tscm, and Th17 are infected or lost at a greater frequency
than in natural host infections (14-16). Similarly, non-natural host infection is marked by
inflammation, structural disruption and fibrosis of lymph nodes, along with high viral burden in the
follicles during chronic infection, which is not observed in natural host infections (17, 61). Limited
infection of these critical subsets and tissue compartments in natural hosts is thought to preserve
immune system homeostasis and function. Therefore, to understand SIV cell targeting and its
contribution to pathogenesis, it is crucial to define expression patterns of these proteins. Initial
studies identified low levels of CCR5 expression as a common feature of natural hosts such as
SM and AGM compared to non-natural hosts such as RM and human, independent of infection.
Interestingly, chimpanzees were found to have moderate levels of CCR5 expression (29).
Furthermore, limited CCR5 expression has since been implicated in protection of certain CD4+ T
cell subsets from infection in SM, such as Tcm and Tscm. While informative, these studies of
CCR5 expression also raised the question of how natural hosts are able to support viremia equal
or above that of non-natural hosts with apparently reduced target cells.
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Our findings that a common feature of natural host viruses is use of species-matched CXCR6
provide an answer to that question. While the field has long known that SIVs can use a variety of
human 7TMR coreceptors to enter cells in vitro, CCR5 was long thought to be the sole coreceptor
used by SIVs in vivo. An early-recognized exception was SIVrcm, whose RCM host is frequently
CCR5-null due to a common deletion allele. SIVrcm cannot use CCR5, and can instead enter
cells using CXCR6 and CCR2b (62, 63). This deletion allele was also found in SM, but at a lower
frequency such that homozygous SM were not identified. However, several years ago, our lab
identified an additional, more common CCR5 deletion allele in SM, and found that animals that
were homozygous for CCR5-null alleles and lacked CCR5 on the cell surface were infected with
SIV at similar rates to CCR5 wild-type animals and maintained high viral loads, indicating that
non-CCR5 entry pathways are used by SIVsmm (59). We then identified CXCR6 as a coreceptor
used by SIVsmm to enter SM lymphocytes, and also found that CXCR6 is used by SIVagmSab to
enter sabaeus AGM lymphocytes (30-32) (Chapter 2). In vitro studies of SIVagmVer, which
infects the vervet subspecies of AGM, found that SIVagmVer can efficiently enter cells expressing
vervet CXCR6 (33). In this study, I add to this mounting evidence of common natural host SIV
CXCR6 use by demonstrating robust use of musCXCR6 by SIVmus to enter transfected cells,
and furthermore extend this emerging paradigm to the natural host ancestor of the HIV-1/SIVcpz
lineage.

This study marks the first functional analysis of SIVmus Env. Unfortunately,

unavailability of MUS lymphocytes prevented us from confirming use of CXCR6 by infecting cells
in the presence of a CXCR6 blocking agent, akin to our SM and sabaeus AGM studies.
Nevertheless, SIVmus represents a distinct lineage of SIV that is the ancestor of HIV-1 env, and
therefore these findings expand the range of known CXCR6-using SIVs and bolster our
hypothesis that CXCR6 use is common to natural host viruses. By identifying yet another natural
host SIV that can use CXCR6 for entry, the need to identify CD4+ cells that express this
coreceptor becomes more imperative to fully understand the implications of this additional entry
pathway and define SIV target cells. This is a question that I address in Chapter 4 of this thesis.

84

Phylogenetic analyses have indicated that a member or ancestor of the SIVgsn/mus/mon lineage
gave rise to env of SIVcpz with cross-species transmission (3-5). Therefore, the finding that
SIVmus was unable to use chimpanzee CD4 for entry was quite unexpected, but might be
explained several ways. First, it is possible that the virus that crossed the species barrier into
chimpanzees was SIVgsn, SIVmon or a close relative thereof, rather than SIVmus; unfortunately,
lack of availability of samples prevented us from testing envelopes of these two viruses. It’s also
possible that none of the present-day viruses of this lineage are able to use CD4, but the
ancestor that actually made the jump could in fact use chimpanzee CD4. Third, it could be that
the entire SIVgsn/mus/mon lineage uses chimpanzee CD4 poorly, but the virus that did cross
could use it sufficiently well to replicate and adapt to use of this receptor in chimpanzee cells.
Cross-species transmission of SIVs generally requires the virus to adapt to its new host; for
example, the emergence of HIV-1 from SIVcpz required a mutation in the matrix protein to
efficiently replicate in human cells (47). It’s tempting to speculate that as SIVgsn/mus/mon Env
adapted to replication using chimpanzee CD4, a casualty of adaptation was loss of CXCR6 use.
Finally, it could be that chimpanzee CD4 has evolved away from an ancient allele that permitted
SIVgsn/mus/mon entry. Given the nonlinearity of the CD4 binding site and the diversity thereof
across SIV strains, it’s difficult to pinpoint the Env residues responsible for the inability to use
cpzCD4 by SIVmus merely by comparing sequences, but future mutagenesis studies could
identify responsible residues. Additionally, restriction of cross-species transmission is a common
theme among SIVs and HIVs. For example, restriction factors often prevent such transmission,
such as TRIM5a restricting HIV-1 replication in Old World monkeys (64). However, to our
knowledge, this is the first time that inability to use CD4 has been identified as a possible point of
restriction in natural cross-species transmission. (Albeit, one that was seemingly overcome.)
Overall, this finding underscores the need for functional analysis in addition to sequence analysis
to fully understand virus/host relationships.
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In summary, I found that CXCR6 could function as an entry coreceptor for yet another natural
host virus, SIVmus, which is in the family of viruses that was the upstream ancestor of the HIV1/SIV lineage. The ability to use CXCR6 was lost with cross-species transfer of this virus into
chimpanzees, as SIVcpz was unable to enter cells expressing species-matched CXCR6, like HIV1. Thus, the loss of CXCR6 use correlates with the emergence of pathogenicity in this lineage of
viruses. Why this coreceptor bottleneck occurred between GSN/MUS/MON and chimpanzees is
unclear, but the need to adapt to replicate efficiently in its new chimpanzee host may have
contributed. Future experiments to define which natural host cells express CXCR6 will help
determine the relationship between CXCR6 use and benign SIV infection.
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Materials and Methods
Cloning MUS and GSN Coreceptors
For GSN and MUS, stored gDNA had been previously isolated from bushmeat samples in
Cameroon. Samples used in this study were MUS 1085 (5) and 1246 (40) (both SIV+), GSN 1289
and 1365 (both SIV-)(41) and GSN42 (SIV+) (41). GSN CCR5, CXCR6 and GPR15 were cloned
from GSN 1365 and CXCR4 was cloned from GSN 1289, and MUS coreceptors were cloned
from MUS 1085.

Coreceptors were amplified as previously described (30, 32). Briefly, previously described
primers that lie outside the open reading frames of the coreceptors that contained restriction
digest sites were used to amplify desired genes from gDNA using Phusion polymerase (New
England BioLabs). For CCR5, CXCR6 and GPR15, PCR products were digested and ligated into
expression vector pcDNA3.1+.

For MUS and GSN CXCR4, the only multi-exon coreceptors amplified from gDNA, each exon
was amplified using primers flanking exon 1 and exon 2. (Sequences that permit TOPO
Directional and/or restriction enzyme digest cloning are underlined.):
CXCR4 Exon 1 Fwd: 5’-CACCGGATCCGCCTGAGTGCTCCAGTAGCCACCGCATCTGG-3’
CXCR4 Exon 1 Rev: 5’-CACATGCAGCCACTGGAACGCTCT-3’
CXCR4 Exon 2 Fwd: 5’-TCACTATGGGAAAAGATGGGGAGGA-3’
CXCR4 Exon 2 Rev: 5’-GTCCCTCGAGACATCTGTGTTAGCTGGAGTGAAAACTTGAA-3’
The amplicons were sequenced and a forward primer was designed that would amplify the
second exon while splicing the two exons together; given that the GSN and MUS sequences
were identical in this region, the same primer was used for both species. This forward primer was
also designed with to permit TOPO Directional cloning into pcDNA3.1/V5-His-TOPO vector
(Invitrogen).
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5’-CACCATGGAGGGGATCAGTATATACACTTCAGATAAC-3’. (Motif to permit TOPO Directional
cloning is in bold. Exon 1 is underlined).

For all coreceptors, DH5a cells were transformed with the ligation products. Constructs were
isolated via MiniPrep (Qiagen) and clones were sequenced using Sanger sequencing and aligned
using the ClustalW algorithm with MacVector 15.5.0.

MUS and GSN CD4
To generate musCD4 and gsnCD4, primers were designed using published human and rhesus
macaque sequence as a template in order to amplify the nine exons of CD4 from gDNA in four
amplicons:
Exons 1-2 Fwd: 5’-CACCCAGCAAGGCCACAATGAAC-3’
Exons 1-2 Rev: 5’-TCAGACACCAAAGGCTTTCA-3’
Exons 3-4 Fwd: 5’-CCCAGCCAGGTAAATGGATA-3’
Exon 3-4 Rev: 5’-TCTCCACTCCTGACCTCCCA-3’
Exons 5-6 Fwd: 5’-GGAGAGGTAGGAAGGAACTGAAG-3’
Exons 5-6 Rev: 5’-GTCTCTGCCAACCACAGGAA-3’
Exons 7-9 Fwd: 5’-AAACCGATTCCCCAGCACT-3’
Exon 7-9 Rev: 5’-GGATCTGCTACATTCATCTGGT-3’
For samples with sufficient DNA, all nine exons were amplified (MUS 1085, GSN 42 and 1289).
For less concentrated samples, only the exons 1-4, which include domain 1, were amplified (MUS
1246, GSN 1365). PCR was performed using Phusion polymerase and the product was run on an
agarose gel. Amplicons of the proper size were purified using a Gel Extraction Kit (Qiagen) and
sequenced using a MiSeq sequencer (Illumina) and sequences were analyzed using Geneious 7
software. For musCD4, all nonsynonymous SNPs occurred within one read-length (150bp), such
that alleles could be determined, and one allele was chosen for synthesis. For gsnCD4, the
nonsynonymous SNPs spanned the entire gene, and therefore a consensus sequence was
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synthesized. The CD4 sequences were synthesized and cloned into the expression vector
pcDNA3.1+ (GenScript).

Chimpanzee coreceptors and CD4
Stored nonviably frozen PBMCs (chimpanzee David) were thawed, and DNA and RNA were
isolated using the QiaAmp Blood Mini Kit (Qiagen) and the RNeasy kit (Qiagen), respectively.
cDNA synthesis from RNA was performed using the Superscript III kit (Invitrogen) using a genespecific primer for CXCR4 (30). Chimpanzee CD4 was previously cloned (44).

SIVmus env cloning
Primers to amplify SIVmus Envs were designed using published sequence data for SIV from
MUS 1085 (accession number AY340700) and MUS 1246 (accession number EF070329). PCR
was performed in two rounds using Expand HF PCR System (Roche), following the
manufacturer’s protocol and using an annealing temperature of 55°C. Round one (35 cycles)
contained outer primers and at least 100ng of gDNA. Round 2 (45 cycles) contained 2uL of the
Round 1 reaction as input and was performed in duplicate with two different sets of inner primer
pairs. Primer sequences are below: set 1 is the outer set, while sets 2 and 3 are inner sets. (The
bases required for TOPO Directional Cloning are bolded.)

MusEnv1085Fwd1: 5’-GTGGAATTTGGAATGAGGTAACGG-3
MusEnv1085Rev1: 5’-TGGTCTAGGAGGTATTGGTCATCT-3
MusEnv1085Fwd2: 5’-CACCTGCTTTTCATTGCGTACTCTGTTT-3
MusEnv1085Rev2: 5’-TATCACAGGTCTTTTACTGGCTCC-3
MusEnv1085Fwd3: 5’-CACCACCTCCTTTGAGTCCTTCTAGGTA-3
MusEnv1085Rev3: 5’-GAAATGCGACATATCCACCATCAG-3
MusEnv1246Fwd1: 5’-ATCCACAATGGTCTGTAGATCAGG-3
MusEnv1246Rev1: 5’-CAAAAGGAGAAGACCAGGAACTCT-3
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MusEnv1246Fwd2: 5’-CACCATGTTGCGCGTTTCACTGTATATT-3
MusEnv1246Rev2: 5’-AGTTTTTGCAGTCTGTCTATGCAC-3
MusEnv1246Fwd3: 5’-CACCTCTAATTCCATGCCAAATGCTGAC-3
MusEnv1246Rev3: 5’-GCACACAAACATTCCTTCTAGTCC-3

Amplification was confirmed by agarose gel and PCR products were column purified (Qiagen
PCR Purification Kit) and ligated into pcDNA3.1/V5-His-TOPO vector using the TOPO Directional
Cloning kit (Invitrogen). Ligation products were transformed into Stbl2 cells and cultured at 30°C.
Colonies were screened for inserts of ~3kb by colony PCR using Taq polymerase and primers
against T7 and BGH. Colonies containing plasmid with properly sized insert were cultured and
plasmids were tested for functionality with backbone pNL4-3Luc E-R+ on 293T cells transfected
to express CD4 and coreceptor. This yielded five distinct functional Envs from MUS 1085, three
of which (1-54, 4-1 and 4-12) were chosen for this study. One PCR reaction yielded 1-54, and
another yielded 4-1 and 4-12. For SIVmus1246, all Envs came from one Round 1 PCR reaction,
but 2 different Round 2 reactions. This yielded five Envs, which were either nonfunctional or
weakly functional.

SIVcpz isolates and envs
SIVcpz infectious molecular clones (IMCs) have been previously reported: SIVcpzPtt strains
MB897, EK505 and MT145 (47) and SIVcpzPts strain BF1167 (35). SIVcpz IMCs were generated
by transfecting IMC plasmids into 293T cells using Fugene 6 reagent. Cells were washed and
media changed 24 hours post transfection, and supernatant was harvested 48 hours post wash.

SIVmus and SIVcpz env mutagenesis
Point mutations to SIVmus1085 1-54 and SIVcpzPtt MT145 envs were made using the
Quickchange II XL Side-Directed Mutagenesis Kit (Agilent). Primers to introduce the mutations
were designed using the manufacturer’s protocol. Plasmids were grown in XL-10 Gold cells and
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mutations were confirmed by sequencing the V3 loop via Sanger Sequencing. The constructs
were also sequenced using a MiSeq sequencer (Illumina) and reads were aligned to the parent
plasmid using Geneious 7 software to confirm that only the intended mutation was introduced.

To generate SIVcpz-musV3, the SIVcpzPtt MT145 Env plasmid was linearized by performing
PCR using outward primers that flanked the V3 loop, such that the entire plasmid was amplified
but the V3 loop was deleted. The V3 loop of SIVmus1085 1-54 was amplified using primers that
contained ~20 bases of homology to SIVcpz MT145 at the regions directly flanking the V3 loop.
The two amplicons were gel purified (Qiagen Gel Extraction Kit) and assembled using the
NEBuilder HiFi DNA Assembly Cloning Kit (New England BioLabs). The assembly product was
transformed into Stbl2s. Colonies were MiniPrepped (Qiagen Kit) and assembly was confirmed by
digesting plasmid with BsteI and running the digest product on a gel.

Analysis of coreceptor function using SIVcpz derived from infectious molecular clones
(IMCs)
CF2th-Luc cells that contain a Tat-driven luciferase reporter cells (8, 65, 66) were cultured in
DMEM containing 3.5% FBS, 1% L-glutamine and 1% pen/strep and plated at 5e5/ well in 6-well
plates for transfection. Cells were transfected with cpzCD4 and coreceptor plasmid (1ug each)
using Fugene 6 reagent. 24 hours later, cells were washed, lifted and replated into 96-well plates.
The following day, cells were infected with 50uL of IMC-derived virus stock. 48 hours postinfection, cells were lysed and luciferase content measured by adding luciferase substrate
(Luciferase Assay system, Promega) and reading relative light units (RLU) on a Luminoskan
Ascent instrument.

Analysis of coreceptor function using luciferase reporter pseudotyped virus
Pseudotyped virus was generated as previously described (30, 32). 293T cells were transfected
with a plasmid containing SIVcpz, SIVmus or SIVgsn env and the luciferase reporter backbone
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pNL4-3LucE-R+ using Fugene 6 reagent. Cells were washed and media changed 24 hours post
transfection, and supernatant was harvested 48 hours post wash. Virus was quantified using a
p24 enzyme-linked immunosorbent assay (ELISA).

Pseudotype infection of 293T cells expressing CD4 and coreceptor were performed as previously
described (30, 32). Briefly, 293T cells were plated and the following day, transfected with
expression plasmids containing species-specific CD4 and a coreceptor. 24 hours later, cells
were lifted using 2mM EDTA and plated into 96-well plates.

The following day, cells were

infected with DNAse-treated pseudotyped viruses via spinoculation at 1200g for 2 hours, then
incubated for 72 hours at 37°C. Cells were lysed using Triton X and luciferase content was
measured by adding luciferase substrate (Luciferase Assay system, Promega) and reading
relative light units (RLU) on a Luminoskan Ascent instrument. Pseudotyped viruses carrying the
vesicular stomatitis virus glycoprotein (VSVg) served as a positive control to ensure any observed
entry

differences

were

coreceptor-specific.

For

infections

using

SIVcpzEK505

and

MT145pseudotypes, SIVcpz MT145 P326A and SIVcpz-musV3, 40uL virus stock was used. For
SIVmus1085 1-54, 4-1, 4-12, 5ng p24 was used.

To confirm expression of CD4 and coreceptor, 293T cells were transfected with CD4 and
coreceptor and infected with pseudotypes expressing previously described SIVsmm Envs
(FTv3.1 and FJV2.1) that use a broad repertoire of coreceptors (30).
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CHAPTER 4

Expression of CXCR6 on Natural and Non-natural Host
Lymphocytes
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Abstract
Nonpathogenic SIVsmm infection of the natural host sooty mangabey (SM) is characterized by
limited infection of certain CD4+ T cell subsets, such as central memory CD4+ T cells (Tcm). In
contrast, pathogenic SIVmac infection of the “non-natural host” rhesus macaque (RM) results in
higher levels of Tcm infection. One mechanism implicated in this relative protection of Tcm in SM
is reduced expression of the entry coreceptor CCR5 on such subsets compared with RM.
However, high-level viremia in infected natural hosts despite low CCR5 levels suggests that other
pathways may support infection, and may target virus to more “dispensable” cell types. Our lab
has identified CXCR6 as a robust SIVsmm coreceptor, and demonstrated that CCR5 is
unnecessary for SIVsmm infection of SM in vivo and ex vivo. In contrast, SIVmac does not use
RM CXCR6. I hypothesized that CXCR6 use by SIVsmm may target virus to CD4+ T cells that
are relatively expendable for immune homeostasis. In this study, I aimed to define expression
patterns of CXCR6 on SM and RM CD4+ T cell subsets. As anti-human CXCR6 reagents do not
cross-react with SM or RM, I generated a monoclonal antibody against primate CXCR6 and
showed that it detects this molecule from multiple primate species. I used flow cytometry to
define patterns of CXCR6 and CCR5 expression on resting and stimulated CD4+ T cells from
SIV-uninfected SM and RM. CXCR6 expression was enriched on effector memory CD4+ T cells
(Tem), but restricted on Tcm as well as naïve CD4+ T cells from both RM and SM. Also, CXCR6
and CCR5 expression define distinct CD4+ T cell populations in both species, with few resting
cells expressing multiple coreceptors. Upon stimulation, the proportion of CXCR6+ CD4+ T cells
increased in both SM and RM; this is distinct from CCR5+ CD4+ T cells, which only increase in
proportion in RM. These findings suggest that CXCR6 targets SIVsmm to CD4+ Tem cells, which
may be less critical for immune homeostasis. These studies also pave the way for analysis of
CXCR6 expression in tissues, in order to more fully define cell targeting determined by use of this
coreceptor.
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Introduction
Over 40 different species of African primates have been identified as endemically infected with
species-specific simian immunodeficiency viruses (SIVs) (1). These “natural hosts”, which include
the sooty mangabey (SM, Cercocebus atys) infected with SIVsmm, generally do not progress to
immunodeficiency despite high viral loads and rapid turnover of infected cells (2-5). This provides
stark contrast to the progression to AIDS observed among infected “non-natural hosts,” such as
humans infected with HIV-1 or macaques infected with SIVmac. Macaques (including rhesus,
cynomolgus and pig-tailed) are Asian monkeys that do not naturally carry SIV; SIVmac emerged
in the laboratory as the result of accidental cross-species transmission of SIVsmm from sooty
mangabeys, and infection of macaques only occurs experimentally (6). Since SIVmac infection of
macaques recapitulates many features of HIV-1 infection in humans, such as widespread CD4+ T
cell loss and chronic activation of the immune system, it is the best model for HIV infection and
pathogenesis to date (7).

Comparative analyses of SIV-infected rhesus macaques (RM, Macaca mulatta) and SM have
permitted detailed interrogation of correlates of disease progression, given the similarities
between the infecting viruses but the drastic differences in infection outcome (8). Such studies
have revealed differences in infection and subsequent disruption of anatomic and cellular
compartments between these two species. First, SIVmac infection of RM is marked by high viral
burden in lymph nodes, as well as lymph node fibrosis and inflammation (9). In contrast, infected
SM have much lower viral burden and lack inflammation in the lymph nodes during chronic
infection, and lymph node structure is maintained (9). Differences have also been found in the
gut, the main site of HIV/SIV replication (10, 11). SIVmac infection of macaques results in drastic
loss of gut CD4+ T cells, concomitant with a loss of barrier integrity and translocation of microbial
products into circulation, which is thought to be a key driver of the chronic immune activation
observed in non-natural host infection (12-15). The disruption of the gut barrier is at least partly
attributed to the loss of CD4+ Th17 cells, which secrete cytokines to maintain gut immunity and
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integrity (16, 17). While SIVsmm infection also causes acute CD4+ T cell loss in the gut, the
CD4+ T cell populations largely rebound after acute infection, Th17 cells and gut barrier integrity
are maintained, and microbial translocation does not occur (16, 18).

SIV (and HIV) replicates in CD4+ T cells, including those with activated or memory phenotypes
(11, 19, 20). Memory CD4+ T cells originate from naïve T cells (Tn) that have been exposed to
cognate antigen, and consist of several distinct types (21-23): stem cell-memory (Tscm), central
memory (Tcm), and effector memory (Tem). Tscm and Tcm largely reside in secondary lymphoid
tissues, such as the lymph node, have regenerative potential and maintain memory T cell
homeostasis. Tem reside mainly in peripheral tissues and have lower replicative potential, a
shorter life span, and enact effector functions in response to re-exposure to an antigen.
Comparative studies of SM and RM have revealed distinct patterns of infection among memory
CD4+ T cells between the two species. In SM, Tcm and Tscm CD4+ T cells, as well as T follicular
helper cells (Tfh), which are critical for germinal center reactions in the lymph node, are infected
less frequently than the same subsets in RM as measured by cell-associated viral DNA (9, 2426). It is hypothesized that restriction of infection of these subsets in SM limits damage to the
anatomic niches where they are found, namely the lymph node, as well as protects the host’s
ability to maintain memory CD4+ T cell homeostasis and replenish lost cells. Recent reports have
also identified protection of Tscm and Tcm from infection in cohorts of viremic, non-progressing
HIV-1 infected humans (27, 28). In RM, it is thought that infection and loss of Tscm and Tcm
result in disruption of immune homeostasis and overall loss of CD4+ T cells. Furthermore, the
consequent critical need for homeostatic CD4+ T cell proliferation likely contributes to chronic
immune activation and immune damage. (Reviewed in (29)).

The main mechanism implicated in protection of Tfh, Tscm and Tcm CD4+ T cells in SM is the
infrequent expression of the entry coreceptor CCR5 (9, 24, 25, 30). However, this raises the
question as to how SM are able to support such high viral loads in the face of few CCR5+ target
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cells. Our lab has shown SIVsmm and several other natural host viruses can use CXCR6 as an
entry coreceptor in addition to CCR5, both in vitro and in primary lymphocytes ex vivo, which may
define additional, previously unrecognized SIVsmm target cells (Chapter 2) (31, 32). SIVmac, in
contrast, is restricted to use of CCR5 in infection of rhesus macaque lymphocytes (32, 33). This
is due to an N terminus polymorphism in rhesus macaque CXCR6, S31R, which renders the
molecule a poor coreceptor for SIVmac (34). To understand which cells are truly targets for
SIVsmm, as well as to address the validity of CCR5 expression restriction as a mechanism of
protection, it is necessary to define expression of CXCR6 on SM CD4+ T cell subsets.

In this study I examined CXCR6 expression on peripheral blood mononuclear cells (PBMC) CD4+
T cell subsets of natural host sooty mangabeys. I hypothesized that CXCR6 expression would be
infrequent on critical CD4+ T cell subsets such as Tn and Tcm, but enriched on the replenishable
Tem subset.

In parallel I examined expression of the canonical coreceptor CCR5.

For

comparison, I examined expression on PBMC subsets from RM, although since SIVmac cannot
use rmCXCR6, it is mainly CCR5 expression that defines potential target cells in this host. To
define CXCR6 expression, we developed a novel anti-nonhuman primate CXCR6 antibody, clone
20D8, because currently available anti-human CXCR6 antibodies do not cross-react with SM and
RM CXCR6. I found that CXCR6 was enriched on CD4+ Tem, and was expressed on a distinct
population from CCR5-expressing cells in both species. These data support a model where
CXCR6 use targets SIVsmm to a unique population of Tem, and likely contributes to the ability to
maintain high viral loads while sparing critical CD4+ T cell subsets that is observed in SIVsmm
infection of SM.
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Results
Development of the anti-primate CXCR6 antibody 20D8
Studies of primate CXCR6 expression have been hindered by the fact that anti-human CXCR6
antibodies do not recognize monkey CXCR6 molecules, including that of SM and RM, when
expressed via transfection of 293T cells (Figure 4.1C) or on SM or RM lymphocytes (data not
shown). Therefore, we generated an anti-primate CXCR6 antibody. Mice were first immunized
using DNA, with three doses of a mammalian expression plasmid containing the gene for
smCXCR6 or rmCXCR6.

This was followed by five intraperitoneal injections of sublethally

irradiated murine B78H1 cells that had been transduced to express smCXCR6 or rmCXCR6
(Figure 4.1A). This immunization strategy ensured that the mice were immunized against CXCR6
in the native transmembrane conformation.

Two mice were immunized with each species’

CXCR6. I then used a cell-based ELISA (cELISA) to screen hybridoma supernatants to identify
antibody clones able to recognize CXCR6 in its native conformation.

I screened over 1400

hybridomas by cELISA, and isolated CXCR6-reactive clones. One clone, 20D8 (from a mouse
immunized with smCXCR6) showed the greatest specific reactivity.

I then further characterized clone 20D8 by evaluating its ability to detect CXCR6 from various
species, and also reactivity against other coreceptors. Transfection of 293T cells followed by flow
cytometry revealed that 20D8 recognizes CXCR6 from all primates tested thus far, including SM,
RM, African green monkey (AGM), as well as human and chimpanzee (Figure 4.1A-B). 20D8 is
specific for CXCR6, as it does not recognize sooty mangabey CCR5, CXCR4, GPR15 or APJ
(Figure 4.1A-B and data not shown).

In contrast, currently available anti-CXCR6 antibodies

(such as K041E5; Figure 4.1.D) detect only human and the closely related chimpanzee CXCR6.
This is the first reagent that detects CXCR6 from multiple primate species.
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CXCR6 is expressed on SM and RM CD4+ lymphocytes and defines a population distinct
from CD4+ CCR5+ T cells.
I then used this antibody to define CXCR6 expression on resting SM and RM peripheral blood
mononuclear cells (PBMC). The staining panel for flow cytometry included markers to define
memory subsets of CD4+ and CD8+ T cells (CD95, CD28, CCR7 and CD45RA) as well as
expression of the coreceptor CCR5.

In both species, CXCR6 was expressed on both CD4+ and CD8+ T cells. Also in both species,
CCR5 and CXCR6 were expressed largely on distinct cell populations, with mainly single-positive
and few double-positive T cells (Figure 4.2A). This result is in contrast to studies of human cells,
where frequent CCR5 and CXCR6 coexpression has been reported (35).

I then quantified expression as the percent positive cells for either or both coreceptors for six SM
and six RM (Figure 4.2B-C). This showed that CCR5-CXCR6+ cells formed a distinct population
of an average of 2% of SM CD4+ T cells. In contrast, CCR5+CXCR6+ cells only averaged 0.3%
of SM CD4+ T cells, while CCR5+CXCR6- cells averaged 1.5% SM CD4+ T cells (Figure 4.2B).
For RM, CCR5-CXCR6+ cells constituted 5.7% of the CD4+ T cells, while CCR5+CXCR6+ cells
averaged 1.6 % of CD4+ T cells, and CCR5+CXCR6- cells averaged 1.4% CD4+ T cells (Figure
4.2C).

A distinct CXCR6+CCR5- population was also observed among CD8+ T cells in the 6 SM and 6
RM, and was particularly large in RM, averaging 33.7% of CD8+ T cells, as opposed to 6.6% in
SM. (Figure 4.2B-C).

Therefore, RM CD4+ and CD8+ T cells had a greater proportion of

CXCR6+ cells than did the same T cell subsets in the SM. RM CD4+ T cells also expressed
slightly more CCR5 than did SM CD4+ T cells, although CCR5 expression on RM CD4+ T cells
measured here was not as frequent as previously reported (24, 30).
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CXCR6 expression is enriched on effector memory CD4+ T cells
Restriction of infection of central memory CD4+ T cells (Tcm) has been associated with the lack
of disease progression in natural hosts as well as HIV-1 viremic, nonprogressing humans, and
low infection of these subsets correlates with low expression of CCR5 on CD4+ Tcm that likely
protects them from infection (24, 26, 28). Given that CXCR6 is a robust natural host SIVsmm
coreceptor like CCR5, I anticipated that its expression would likewise be restricted on Tcm. Thus,
I also defined CXCR6 expression on memory CD4+ T cell subsets (Figure 4.3). CXCR6
expression was infrequent among on CD4+ Tcm cells (1.0% of CD45RA- CCR7+ CD4+ T cells)
and naïve CD4+ T cells (Tn) (0.5% of CD45RA+, CCR7+, CD28+, CD95- CD4+ T cells), but
enriched on effector memory CD4+ T cells (Tem) (5.9% of CD45RA-, CCR7- CD4+ cells) (Figure
3). This expression pattern is consistent with reported SIVsmm infection patterns of SM memory
CD4+ T cells (24, 25). Furthermore, CXCR6 restriction on Tcm and enrichment on Tem was
found for both RM and SM, showing that this pattern of expression is not necessarily specific to
natural hosts (although CXCR6+ Tem were more frequent in RM, where 22% of Tem expressed
CXCR6).

The selected memory markers did permit staining of stem-cell memory CD4+ T cells (Tscm)
(CD45RA+, CCR7+ CD28+, CD95+). However, I identified very few of these cells in these PBMC
samples, preventing meaningful analysis of this subset. That being said, the few cells collected
had very little CXCR6 expression (data not shown).

The frequency of CXCR6+ cells increases in response to mitogen stimulation
I then measured changes in CCR5 and CXCR6 expression patterns upon mitogen stimulation.
Previous studies have shown that the proportion of CCR5+ cells does not increase upon
stimulation of SM PBMC, but does increase upon stimulation of RM PBMC (24). To identify any
changes in the proportion of CXCR6+ cells following stimulation, I stained SM and RM PBMC for
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CD4 and coreceptor expression prior to stimulation (Day 0), and then at days 5, 7 and 9 post
stimulation with concanavalin A and IL-2.

For both SM and RM, the average proportion of CXCR6+ cells at 5 days post stimulation had
increased from baseline. This increase was from an average of 1.6% to 5.6% for SM, and from
an average of 8.1% to 16% among RM (Figure. 4.4). The frequency of CXCR6+ CD4+ T cells
then decreased slowly over the remaining time points. In contrast, the proportion of CCR5+ cells
first decreased in response to stimulation for both species, in agreement with published findings
(24). By day 9 post-stimulation, the proportion of CCR5+ cells remained below baseline for SM
CD4+ T cells (Baseline: 3.3%; Day 9: 0.9%), but increased dramatically for RM CD4+ T cells
(Baseline: 5.6%; Day 9: 34.7%). These data demonstrate that the proportions of CXCR6+ and
CCR5+ CD4+ T cells change distinctly in response to stimulation within each species, and
suggest that expression of these coreceptors may be regulated differently.
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Figures

Figure 4.1: Generation of anti-CXCR6 antibody 20D8. A. Balb/c mice were immunized with 3 doses of
mammalian expression plasmid containing the genes for either rhesus macaque (RM) or sooty mangabey
(SM) CXCR6, followed by 5 doses of sublethally-irradiated B78H1 cells expressing RM or SM CXCR6. B.
293T cells were transfected with expression plasmids containing one of eight primate CXCR6 genes, SM
CCR5 or empty vector. 48 hours later, cells were stained with mouse anti-primate CXCR6 antibody 20D8 +
a goat anti-mouse secondary (B), secondary only (C) or a commercially available anti-human CXCR6
antibody (D).
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Figure 4.2: CXCR6 and CCR5 are expressed largely on distinct sooty mangabey and rhesus
macaque T cell populations. A. Resting SM CD4+ T cells (far left) and CD8+ T cells (mid left), as well as
RM CD4+ T cells (mid right) and CD8+ T cells (far right) were stained for both CCR5 (y-axis) and CXCR6 (xaxis). Numbers in the quadrants are the percent of CD4+ or CD8+ T cells expressing the respective
combination of coreceptors. One representative animal is shown. B, C. Summary of CCR5 and CXCR6
single- and co-expressing cells as the percent of total CD4+ and CD8+ T cells from 6 SM (B) or 6 RM (C).
Reported values represent percent of cells that stained positive for CXCR6 using 20D8 + a secondary
antibody minus the percent of cells that stained positive using the secondary alone.
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Figure 4.3: CXCR6 expression is enriched on effector memory CD4+ T cells (Tem) Resting sooty
mangabey (SM) and rhesus macaque (RM) peripheral blood mononuclear cells were stained using
antibodies to define CXCR6 expression of CD4+ memory subsets: naive (Tn: CD45RA+ CCR7+ CD28+
CD95-), central memory (Tcm: CD45RA- CCR7+) and effector memory (Tem: CD45RA- CCR7-). A. CXCR6
expression (x-axis) of memory subsets of one representative sooty mangabey (top panels) and one rhesus
macaque (bottom panels). CD14, included in the panel to exclude monocytes in gating, is shown on the yaxis as it permits clear visualization of CXCR6+ cells. B. The proportion of CXCR6+ cells in CD4+ Tn, Tcm,
and Tem subsets for 6 SM and 6 RM. Values displayed represent percent of cells that stained positive for
CXCR6 using 20D8 + a secondary antibody minus the percent of cells that stained positive using the
secondary alone.

110

RM CCR5 and CXCR6

Copy of SM CCR5 and CXCR6- together

50

Sooty mangabey

40

% coreceptor + cells

% coreceptor + cells

50

30
20

CXCR6
CCR5

40

CXCR6
CCR5

30
20

CXCR6
CCR5

10

10
0

Rhesus macaque

0

5

7

9

0

Days post stimulation

0

5

7

9

Days post stimulation

Figure 4.4: The proportion of CXCR6 positive cells increases in response to stimulation for both
sooty mangabey and rhesus macaque CD4+ T cells. Cryopreserved sooty mangabey (SM) and rhesus
macaque (SM) peripheral blood mononuclear cells were thawed, rested overnight, and then stained (Day 0)
or stimulated with Concanavalin A and IL-2. Approximately ½ cells were removed and stained per timepoint
(Day 5, 7 and 9) for CD4 and coreceptor expression. Coreceptor expression of SM CD4+ T cells (n=5) is
shown in the left panel and RM CD4+ T cells (n=7) are shown on the right.
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Discussion
Natural hosts of SIV, such as the sooty mangabey (SM), do not progress to AIDS despite high
plasma viremia. One mechanism that likely contributes to this infection outcome is distinct
targeting of SIV among CD4+ T cell subsets. Specifically, the protection of certain critical CD4+ T
cell subsets and anatomic niches from infection likely preserves immune system function in
natural hosts. Conversely, targeting of infection in these hosts to more replenishable, expendable
CD4+ T cell subsets results in high viral loads. Our group recently showed that CXCR6 is widely
used by SIVs that infect natural hosts, which are known to express very low CCR5 levels,
including SIVsmm infection of SM PBMC. Here, I showed that CXCR6 follows an expression
pattern on natural host SM memory CD4+ T cells that is consistent with such a model: naïve (Tn)
and central memory (Tcm) CD4+ T cells, which are required for maintaining CD4+ T cell
homeostasis, had very limited CXCR6 expression, while effector memory (Tem), which are
replenishable, were enriched in CXCR6 expression. A similar expression pattern was found in
the non-natural host RM, although this is not likely to impact SIV targeting in this species since
SIVmac does not use rmCXCR6 for entry, and RM express high levels of CCR5. Furthermore,
CXCR6+CCR5- cells formed a distinct subset of CD4+ T cells in RM and SM. For SM, this
identifies a previously unacknowledged target cell population in this host that likely contributes to
the high viral loads observed in SM despite infrequent CCR5 expression.

While we only

examined CXCR6 expression here in SM, this pattern may be relevant to other natural hosts
whose endemic viruses also use species-matched CXCR6 efficiently, such as African green
monkeys infected with SIVagm.

Between RM and SM, CXCR6 expression patterns across memory subsets were generally
conserved, namely restriction of expression on Tcm and enrichment on Tem. While this suggests
that similar mechanisms regulate expression in both species, subtle differences were noted. A
smaller proportion of SM CD4+ Tem cells expressed CXCR6 than did RM CD4+ Tem cells (SM:
5.8% CXCR6+ Tem; RM: 22% CXCR6+). This could reflect evolutionary pressure on SM to
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moderate the frequency of this SIVsmm coreceptor and respective CXCR6+ target cells. RM has
faced no such pressure, as it is not endemically infected with SIV, CXCR6-using or otherwise.

With the development of the anti-primate CXCR6 antibody 20D8, many additional studies can be
performed to investigate the contribution of CXCR6 use to natural host SIV cell targeting and
infection outcome.

First, as the bulk of SIV replication (and pathology in non-natural host

infection) occurs in the lymph node and the gut (10), it will be necessary to define CXCR6
expression patterns in these relevant tissues by flow cytometry or immunohistochemistry. I
hypothesize that CXCR6 expression would be infrequent in the lymph node, particularly on Tfh
cells, corresponding to the low viral burden observed in this compartment in SM (9). I hypothesize
that CXCR6 expression would be higher in the gut, where the bulk of virus replication occurs;
however, CXCR6 expression would likely be minimal on Th17 cells that contribute to the
maintenance of gut barrier integrity and immunity (16). Th17 cells are maintained in natural host
infection, and therefore are unlikely to be SIVsmm targets. Akin to the data regarding peripheral
CD4+ T cell subsets shown here, a comparison between SM and RM will offer clues as whether
CXCR6 expression is differentially regulated by natural and non-natural hosts in these
compartments.

Although characterization of nonhuman primate CXCR6 is limited to the expression data shown
here, studies of other species may offer insight into the function and expression of CXCR6 in
general. Studies in humans and rats suggest that CXCR6 defines extra-lymphoid homing T cells
and is largely excluded from lymph nodes (36, 37). A similar finding in natural hosts would
suggest a low frequency of CXCR6+ target cells in this tissue and be consistent with the low virus
burden observed in lymph nodes of SM and AGM. In humans, CXCR6 expression has been
described primarily on memory CD4+ T cells, particularly Th1 cells, although expression on Th17
cells and naïve T cells has been reported as well (35, 36, 38, 39). Here, expression of CXCR6 on
effector memory, but not naïve CD4+ T cells was observed in both SM and RM. CXCR6 can also
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be found on human cells that lack CD4 and are therefore not virus targets, such as CD8+ T cells,
which was also observed for SM and RM in this study, and NKT cells (35, 36, 40). Human
CXCR6 mRNA has been isolated from the placenta, small intestine, thymus and spleen (41);
protein expression has been found in the liver, but otherwise is not well defined (42). (The
function of CXCR6 and its ligand CXCL16 are discussed in Chapter 5.) Direct investigation of
CXCR6 expression in natural hosts will be required to identify the frequency and location of
CD4+CXCR6+ target cells of SIV. Given that SIV has been endemic among natural hosts for
hundreds of thousands of years or more, it is possible that the expression pattern of this
coreceptor in natural hosts vary from that of humans due to host evolution with the virus.

Studies of human lymphocytes have found that CXCR6 and CCR5 are frequently coexpressed on
the same population of cells (35). However, in this study of SM and RM lymphocytes, CXCR6
and CCR5 expression largely defined two populations of single-coreceptor expressing CD4+ and
CD8+ T cells. This suggests that CXCR6 expression patterns in humans may not reflect those of
nonhuman primates, and supports the need for direct studies of natural host tissues to identify
CXCR6-expressing target cells.

Additional CD4-expressing cells for which CXCR6 expression ought to be defined include CD4+
T regulatory cells (Tregs), which reduce the effector activity of other immune system cells, and
macrophages.

Whether natural host Tregs serve as target cells is unclear; a recent study

identified frequent infection of this subset in SIVmac infection of RM (43), but CD4+ Treg infection
in natural hosts remains undefined. The role of Tregs in natural host infection is likewise
uncertain; studies of AGM suggest Treg activity contributes to control of immune activation (44),
but studies of SM did not find such a contribution (45). Measuring CXCR6 expression on CD4+
Tregs will inform whether these cells can serve as SIVsmm targets. SIV infection of macrophages
has generally been studied in the context of CD4+ T cell depletion. These studies have shown
that macrophages can serve as SIV targets in infection of RM (46), but are likely an insignificant
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target population in infection of SM (20). A lack of CXCR6 expression by macrophages could be
a contributing factor.

In addition to SIVsmm, other natural host viruses can use CXCR6 for entry: SIVagmSab (ex vivo,
Chapter 3) and SIVagmVer (in vitro, species-matched coreceptor)(33), which infect sabaeus and
vervet AGM, respectively, and SIVrcm (in vitro, human coreceptor)(47, 48), which infects redcapped mangabeys (RCM). Identifying which cells express CXCR6 in these species will define
the breadth of the restriction of CXCR6 expression to CD4+ Tem observed here for SM. To
investigate vervet AGM CXCR6 expression patterns prior to the generation of anti-CXCR6 20D8,
Riddick et al quantified CCR5 and CXCR6 mRNA in naïve and memory T cells of vervet AGM as
well as RM (33). Surprisingly, they found high CXCR6 mRNA levels in naïve CD4+ T cells in
both species; this contrasts with the finding here of little CXCR6 expression on naïve CD4+ T
cells in RM.

However, RNA expression does not necessarily predict protein expression; if

expressed at the protein level it would suggest that naïve T cells could be targets for SIVagmVer,
which would be unexpected. Thus, it will be necessary to stain vervet AGM PBMC to define
surface expression of CXCR6, as well as correlate CXCR6 mRNA and surface expression levels
within a variety of species to determine the relationship between these two values and if posttranscription regulatory pathways exist for expression of this coreceptor.

Both AGM and RCM have evolved specific mechanisms that help protect cells from SIV infection
that are not found or are less common in SM. For AGM, CD4+ T cells downregulate CD4 upon
entry into the memory pool. This occurs independently of infection, and these CD4- cells are still
able to carry out helper functions (49-51). In contrast, RCM have evolved a genetic mechanism
that is hypothesized to protect CD4+ T cells, as a CCR5-null allele is common among this
species, resulting in homozygous animals that lack CCR5 on the surface of their CD4+ cells.
While such a mechanism exists in SM (52), it is much more common in RCM, where 73% of
genotyped RCM (n=15) were homozygous for this allele (48). Furthermore, SIVrcm cannot enter
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cells using CCR5, but instead can use CXCR6 and CCR2b (in vitro, human receptor)(47, 48).
These additional CD4+ cell protection mechanisms found in AGM and RCM have possibly
exerted distinct pressure on CXCR6 expression in these hosts, and staining for CXCR6 will
elucidate whether this resulted in distinct CXCR6 expression patterns from SM in these natural
hosts.

While published data from our lab demonstrates a clear role for CXCR6 in SIVsmm infection (31,
32, 52), the relationship between CCR5 and CXCR6 and cell targeting in vivo remains to be
definitively established. The development of the anti-NHP CXCR6 antibody 20D8 now allows
such experiments.

To identify coreceptor entry pathways used by SIVsmm in vivo, cell-

associated viral DNA could be measured in PBMC from SIV+ SM sorted by double, single or no
CCR5 and CXCR6 expression to define the proportion of infected cells among each subset.
These studies could be complimented by ex vivo experiments investigating the relative
permissiveness of CCR5 and CXCR6 expressing cells, where SM PBMC would be infected with
SIVsmm and stained for coreceptor expression and the presence of virus (either by staining for
the capsid protein p27 or by using a GFP reporter virus).

CCR5 and CXCR6 were largely expressed on distinct CD4+ T cells in both RM and SM.
Furthermore, expression patterns of these coreceptors on PBMC diverged in response to
mitogenic stimulation, with SM and RM CXCR6 expression peaking earlier, RM CCR5 expression
peaking later, and SM CCR5 expression remaining low throughout. Together, these data suggest
that distinct mechanisms regulate the expression of CXCR6 as compared to CCR5, and CCR5 in
RM as compared to SM. These data also suggest that regulation of expression of these
coreceptors in monkeys is distinct from that in humans, where coordinate CCR5 and CXCR6
expression has been reported (35). Further studies are warranted to discern how this regulation
occurs, such as whether such differences emerge at transcription due to distinct promoter
elements, or later, such as protein regulation due to production of their respective cytokines.
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Also, this analysis showed changes in the frequency of coreceptor expressing cells over time, but
did not distinguish between increases due to upregulation of coreceptor expression and death of
non-coreceptor expressing cells. Future studies require marking dividing cells with a dye such as
carboxyfluorescein succinimidyl ester (CFSE) and measuring coreceptor expression of divided
cells in order to determine if activated, replicating cells upregulate CXCR6. Lastly, in this study,
PBMC were stimulated with concanavalin A to induce robust activation.

However, a more

biologically relevant stimulation could be using antibodies against CD3 and CD28. Such
experiments will be facilitated by the recent generation of a conjugated version of 20D8.

In addition to ex vivo activation, changes in the frequency of the CXCR6+ CD4+ T cell population
likely change in response to in vivo activation; namely, in response to SIVsmm infection. An
important experiment to address this would define coreceptor expression in one cohort of RM and
SM by measuring the frequency of CXCR6+ cells prior to experimental SIV infection, then at
several time points in both the acute and chronic phases, as has been done for CCR5 expression
in these species (24). However, given that current regulations prevent the experimental infection
of SM, cells from distinct populations of uninfected and infected primates would need to be
compared instead, which would identify general changes in the population of CXCR6+ cells due
to SIV infection.

One caveat of this study is that the observed frequency of CCR5 positive cells was lower than
previously reported studies, particularly for RM (24, 30). This may be due to the fact that the
available samples for this study were cryopreserved CD4+ T cells, and freezing is known to
reduce the frequency of CCR5 expression (53). To more accurately measure frequency of
CCR5+ cells in comparison to CXCR6+ expressing cells, a study using whole blood, where CCR5
expression is most robust, is warranted. However, it is unlikely that such analysis would alter the
observation that CXCR6 expression is generally on a population of CD4+ T cells distinct from
those expressing CCR5.
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One feature of natural host infection observed in both SM and AGM is a low frequency of mother
to infant transmission (MTIT). Studies in both species have found this low rate corresponds to a
low frequency of CCR5+CD4+ target cells (54-56). In order to fully understand this phenotype,
the frequency of CXCR6+CD4+ cells in infant and juvenile animals must also be measured. A
recent study of MTIT in SM by Chahroudi et al measured mRNA of CXCR6 and did find a low
frequency of CXCR6 mRNA in infant SM (56), suggesting that CXCR6 surface expression in this
cohort is likely low as well.

In summary, these data identify effector memory CD4+ T cells in peripheral blood as CXCR6expressing target cells for SIVsmm infection of sooty mangabeys. The finding that CXCR6
expression is restricted on naïve and central memory CD4+ T cells, as is CCR5 expression,
suggests that these cells are protected from infection and use of CXCR6 targets virus towards
more differentiated and likely expendable cell populations in natural hosts. The future studies
described here, made possible by the generation of the novel anti-primate CXCR6 antibody
20D8, will elucidate the degree to which CXCR6 contributes to cell targeting and maintenance of
immune function observed in natural hosts.
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Materials and Methods
Generation of anti-primate CXCR6 monoclonal antibody 20D8
To generate a CXCR6-expressing cells as an immunogen, a plasmid was made with GFP fused
to the C-terminus of RM CXCR6 and SM CXCR6 (rmCXCR6-GFP or smCXCR6-GFP). Proper
translation and expression of the construct was ensured by testing the ability of the CXCR6-GFP
gene products to permit SIVsmm entry. The CXCR6-GFP genes were then inserted into the
lentiviral vector pELNS. Cells of the murine line B78H1 were transduced with the vectors, and
GFP-high cells were selected for immunization of mice.

Balb/c mice were immunized against SM CXCR6 or RM CXCR6 by three hydrodynamic tail vein
injections of pcDNA3.1+ containing SM or RM CXCR6 (15 ug plasmid each) given one, three and
four weeks after a pre-immunization bleed. Five weeks later, mice began a series of five biweekly intraperitoneal injections of smCXCR6-GFP or rmCXCR6-GFP high-expressing B78H1
6

6

cells that had been sublethally irradiated (10 x 10 cells per injections 1-3, 50 x 10 cells per
injections 4 and 5). One week after the final immunization, spleens were harvested and
hybridomas were generated by fusing splenocytes with the Sp2/0 myeloma cell line.

Hybridoma supernatants were screened for production of CXCR6 reactive antibody by a 293T
cell-based ELISA (cELISA; modified from Atanasiu et al, JVI 2016, (57)). 293T cells were
transfected with an expression vector containing smCXCR6, rmCXCR6 or empty vector. 48 hours
later, cells were lifted with 2mM EDTA and resuspended in 3%BSA in PBS+ Mg

2+

2+

and Ca . 1e5

cells were plated/well in a 96 well plate and incubated 30 min at room temperature. Plates were
spun, buffer aspirated and incubated for 1 hour with hybridoma supernatant at 4°C. Plates were
spun and cells washed twice with PBS + Mg

2+

2+

and Ca . Cells were resuspended in a 1:100

dilution of goat anti-mouse horseradish peroxidase (HRP) antibody in 3% BSA and incubated for
1 hr at room temperature. Cells were washed with PBS twice, then fixed with 3% PFA. Plates
were spun, PFA aspirated and cells washed with 20mM ph4.5 sodium citrate. Plates were spun,
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citrate buffer removed and HRP substrate was added. Color was allowed to develop for 15
minutes and hybridoma supernatant reactivity with cells expressing CXCR6 vs. cells not
expressing CXCR6 was determined visually. Over 1400 hybridomas were screened, and one was
identified (20D8) from an smCXCR6-immunized mouse that was reactive by cELISA with cells
expressing smCXCR6, but not cells transfected with empty vector.

To determine the breadth of primate CXCR6 recognition by 20D8, 293T cells were transfected
with pcDNA3.1+ containing human, chimpanzee, mustached monkey, greater spot-nosed
monkey, RM, SM, sabaeus AGM, or vervet AGM CXCR6, or SM CCR5 or empty pcDNA3.1+
vector. (Genes not cloned in this paper were previously cloned by us or collaborators.) 48 hours
later, cells were lifted and stained with unconjugated 20D8 followed by APC goat anti-mouse IgG
2° (Poly4053, BioLegend), the 2° alone or anti-human CXCR6 AF647 (K041E5, BioLegend).

CXCR6 expression on sooty mangabey and rhesus macaque PBMC
PBMC were isolated from six SM, 5 of which were homozygous for wild-type CCR5, and one of
which was heterozygous for the CCR5 ∆2 mutation (52). Cells were thawed and rested overnight
in RPMI supplemented with 10% FBS, 1% L-glutamine and 1% pen/strep prior to staining.

SM PBMCs were thawed and rested overnight in RPMI supplemented with 10% FBS, 1%
pen/strep and 1% L-glutamine. Cells were first stained with the anti CXCR6 clone 20D8, followed
by a goat-anti mouse AF488 secondary (Poly4053, BioLegend). The cells were then washed and
stained with Aqua Live/Dead Dye (Invitrogen) and the remaining surface antibodies: anti-CD3
APC-Cy7 (clone SP34-2, BD Pharmingen), anti-CD4 PECy5.5 (clone S3.5, Invitrogen), anti-CD8
BV570 (clone RPA-T8, BioLegend), anti-CCR7 (clone G043H7, BioLegend), anti-CD95 PECY5
(clone DX2, BD Biosciences) anti-CD28 ECD (clone CD28.2, Beckman Coulter), anti-CCR5 PE
(clone 3A9, BD Pharmingen), anti-CD45RA PE Cy7 (clone 5H9, BD Pharmingen), anti-CD20
BV650 (clone 2H7, BD Horizon), anti-CD16 BV650 (clone 3G8, BioLegend), anti-CD14 BV605
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(M5E2, BioLegend). Cells stained with the entire surface panel but with the AF488 secondary
antibody only (and not unconjugated 20D8) were stained in parallel to define non-specific staining
by the secondary. The gate for CXCR6 expression was then drawn on the cells stained with the
secondary antibody only. As slight non-specific staining by the secondary was observed, the
reported percent positive cells for CXCR6 staining were calculated by subtracting the percent of
AF488 positive cells in the secondary only condition from the anti-CXCR6 20D8 plus secondary
condition. Samples were run on an LSRII and data analyzed using FlowJo software (v. 9.9).
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CHAPTER 5

Discussion
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Natural hosts of SIV do not develop immunodeficiency despite high viremia, and this mutually
satisfactory relationship between virus and host is likely the product of hundreds of thousands of
years of coevolution (1). Understanding the mechanisms by which these nonhuman primates
(NHP) are able to maintain high level viremia yet not develop disease will further elucidate the
incompletely understood mechanisms of pathogenesis in primate lentivirus hosts that do progress
to AIDS, such as HIV-1 infected humans.

Of the many mechanisms that have been implicated in immunodeficiency of non-natural hosts, a
common thread is infection and loss of certain critical CD4+ T cells that are maintained in natural
hosts. Preservation of these subsets, such as central memory CD4+ T cells (Tcm) and Th17
cells, paired with infection of more expendable CD4+ T cells, likely supports viremia without
progression to disease. Thus, an essential question to answer to understand SIV/HIV
pathogenesis is what defines target cells of natural hosts, and how this differs in infection in nonnatural hosts. Earlier work from my lab indicated that use of the coreceptor CXCR6 by SIVsmm
to enter primary T cells from its natural host, the sooty mangabey (SM), distinguished this
infection from pathogenic infections such as HIV-1 and SIVmac, which are largely restricted to
use of species-matched CCR5 and do not use CXCR6 for entry (2-4). In this thesis, I aimed to
expand upon this finding by defining the breadth of CXCR6 use among additional natural host
SIVs, investigating the coreceptor use patterns and relationship to pathogenesis within the virus
lineage that gave rise to the HIV-1 pandemic, and identifying SIVsmm target cells defined by
expression of this coreceptor in SM.

I have presented data showing that SIVagmSab (Chapter 2) and SIVmus (Chapter 3) can use the
species-matched coreceptor CXCR6 in addition to CCR5 in vitro, and verified use of this entry
pathway in SIVagmSab infection of sabaeus lymphocytes (Chapter 2). When added to published
work from our lab and others demonstrating species-matched CXCR6 use by SIVsmm in vitro
and ex vivo (3, 4), and by SIVagmVer in vitro (5), my data support the conclusion that CXCR6
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use is a common feature of natural host SIVs. This feature is in stark contrast to HIV-1, SIVmac
and SIVcpz (Chapter 3) that cannot use CXCR6 in addition to CCR5 and are pathogenic in their
respective hosts.

This recurrent association between CXCR6 use and lack of pathogenesis

suggests that infection of CXCR6-expressing target cells contributes to this phenotype in natural
hosts.

The finding that SIVmus can use species-matched CXCR6 for entry, while SIVcpz cannot, has
implications beyond bolstering the relationship between lack of pathogenesis and CXCR6 use. A
virus of the lineage to which SIVmus belongs gave rise to the envelope gene of SIVcpz (6, 7);
therefore, use of CXCR6 was seemingly lost in the emergence of SIVcpz, and restriction to CCR5
as a coreceptor is associated with the emergence of pathogenesis in the new chimpanzee host.
This restriction to CCR5 use from CXCR6 and CCR5 use parallels observations made when
comparing the non-natural host virus SIVmac to its natural host virus ancestor SIVsmm.

Finally, I provided the first analysis of CXCR6 expression on nonhuman primate (NHP) peripheral
blood cells, and found that CXCR6 expression is enriched on effector memory CD4+ T cells
(Tem) and largely defines a separate population of CD4+ T cells than does CCR5 expression in
both SM and rhesus macaques (RM). These data suggest that CXCR6 expression defines a
previously unrecognized population of SIV target cells in SM. Collectively, the data in this thesis
suggest that entry through CXCR6 (in addition to CCR5) by natural host SIVs (which express low
levels of CCR5) is a key feature of natural host viruses that may permit high levels of viremia
without immunodeficiency.

Differential targeting by natural and non-natural SIV/HIV
Many studies have demonstrated that natural and non-natural host infections have distinct
patterns of tissue and cell targeting. Natural host infections are characterized by low viral burden
in lymph nodes, including among T follicular helper cells (Tfh) (8-11), low frequency of infection of
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central memory (Tcm) and stem cell memory (Tscm) CD4+ T cells (12, 13), and maintenance of
Th17 cells in the gut (14).

In contrast, non-natural host infections have high viral burden,

inflammation and progressive fibrosis in lymph nodes, including infection of Tfh, (15, 16), higher
frequency of Tcm and Tscm infection, which likely disrupts CD4+ T cell homeostasis, as well as
drastic Th17 cell loss, which likely contributes to microbial translocation and chronic immune
activation (17-19). As receptor and coreceptor expression is the primary determinant of HIV and
SIV target cells, virus coreceptor use likely influences these differences in cell targeting and
therefore pathogenicity.

Early studies of natural hosts quickly identified restricted SIV cell targeting as a possible
mechanism to maintain immune system function despite viremia, defining limited CCR5
expression as a common feature of natural hosts that occurred independent of infection status
(20). Detailed studies of SM showed that this restriction is particularly profound in memory CD4+
T cell subsets with greater regenerative potential, including Tcm and Tscm (12, 13).

While

restriction of CCR5 expression likely contributes to protection of certain CD4+ T cell subsets, it
raises the question of how natural host infections are able to maintain high viral loads in the face
of limited target cell frequency and the observed high turnover of infected cells (21). The
identification of CXCR6 as a robust coreceptor for SIVsmm (3, 4) and SIVagmSab (Chapter 2)
suggests that CXCR6 expressing cells are also SIV targets, and could define additional,
previously unrecognized SIV target cells.

By developing anti-NHP CXCR6 antibody 20D8, I was able to address which peripheral CD4+ T
cells express CXCR6 and therefore are targets of SIVsmm infection of SM. As described in
Chapter 4, I found that CXCR6 expression was restricted on undifferentiated (naive, Tn) and less
differentiated memory CD4+ T cell subsets (Tcm). This expression pattern corresponds with data
suggesting that protection of Tcm from infection is paramount to maintaining immunocompetence
in SM as well as rare viremic non-progressing HIV-1 infected humans (12, 22). In contrast,
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CXCR6 expression was enriched on effector memory CD4+ T cells, which are considered more
expendable and may be able to support viremia without putting a strain on memory CD4+ T cell
homeostasis (23, 24). Furthermore, the identification of CXCR6+CCR5- CD4+ T cells identifies a
novel population of SIVsmm target cells that when added to the infrequent population of
CCR5+CD4+ T cells increases the total proportion of CD4+ T cells that can serve as targets and
support high viremia.

MODEL: Divergent entry pathways between natural and non-natural hosts
of SIV
Considering that entry is a key determinant of SIV target cells, I propose a model of natural host
SIV infection whereby use of CXCR6 (and possibly other alternative coreceptors), concomitant
with a low frequency of CCR5+ cells, targets natural host SIVs towards more replenishable CD4+
T cell subsets (Figure 5.1). Infection of such CXCR6-expressing replenishable cells would permit
replication to high titers without causing the destruction of T cell homeostasis and lymph node
and gut architecture that characterizes pathogenic infection. Due to their enriched CXCR6
expression (Chapter 4) and limited role in maintaining the memory CD4+ T cell pool (25-27),
CD4+ Tem cells likely represent one such replenishable subset. In support of this, the frequency
of infection CD4+ Tem, but not Tcm, was found to correlate with plasma viral load in sooty
mangabeys (8). In contrast, in non-natural host infections, where CCR5 but not CXCR6 is used
for entry, a higher frequency of CCR5+ CD4+ T cells targets the virus to various compartments,
including the lymph node, gut, and more critical CD4+ memory T cell subsets such as Tcm.
Consequently, gut and lymph node integrity is lost and T cell homeostasis is disrupted, driving
chronic immune activation, prolonged CD4+ T cell homeostatic proliferation and the progression
to immunodeficiency. These non-natural host viruses include HIV-1, SIVcpz and SIVmac, all of
which are the results of cross-species transmission events, suggesting that cross-species
transmission to a naïve host may trigger this altered targeting.
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To investigate this model, a necessary next step is to define CXCR6 expression (and CCR5
coexpression) in the major sites of SIV replication: the gastrointestinal tract and the lymph node.
From the model, I hypothesize that CXCR6 expression would be enriched in the gut, where most
natural host SIV replication occurs (28, 29), but only on cell subtypes that would not contribute to
disruption of barrier integrity when infected and lost. In contrast, I hypothesize that CXCR6 cells
would be present at a low frequency in the lymph node, which carries reduced viral burden in
natural hosts (8, 9). Studies of sooty mangabey lymph node infection have demonstrated that
SIVsmm replication occurs largely outside the follicles (8). Therefore, I would hypothesize that
any CXCR6 expression present is likewise excluded. Furthermore, T follicular helper CD4+ cells
(Tfh) that reside in the lymph node are also infected less frequently in natural hosts (8),
suggesting CXCR6 expression would be restricted on this subset as well. Prior to performing
these studies, some insight into possible CXCR6 tissue distribution patterns can be gleaned from
analysis of murine and human studies, which largely agree with these predictions, as studies in
humans and rats suggest that CXCR6 characterizes extra-lymphoid homing T cells (30, 31). In
humans, CXCR6 mRNA has been isolated from the placenta, small intestine, thymus and spleen
(32).

That being said, it is quite possible, if not likely, that patterns of CXCR6 expression differ between
NHP and humans. Studies of CXCR6 expression in human peripheral lymphocytes have
described frequent coexpression of CCR5 and CXCR6 (33). This is distinct from my finding of
largely segregated CCR5 and CXCR6 expressing cells in SM (and RM) lymphocytes (Chapter 4).
This suggests that monkey expression patterns may be distinct from those found in humans.
Furthermore, human studies have found CXCR6 expression on tonsil Th17 cells (34). From our
model, I hypothesize that Th17 cells, which are maintained in natural host infection and therefore
unlikely to be target cells, would not be enriched in CXCR6 expression.

Defining CXCR6-

expressing cells in natural host tissues by flow cytometry or immunohistochemistry will test these
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predictions. Staining SM, RM and human tissue in parallel will provide insight as to whether
CXCR6 expression in tissues is regulated differently between natural and non-natural hosts.

Defining the phenotype of CXCR6-mediated targeting
If CXCR6 expression in RM mirrors that of SM in tissues as it does in the blood, infecting
macaques with a virus restricted to use of rmCXCR6 would help define the degree to which
targeting mediated by CXCR6 contributes to infection outcome. Such a virus could be generated
by serially passaging SIVmac on a mixture of engineered SupT1 cells where the proportion of
cells expressing rmCXCR6 greatly exceeds those expressing rmCCR5, followed by passaging on
cells expressing rmCXCR6 only, thus allowing replication but prompting evolution to use
rmCXCR6 (akin to generation of CD4-independent SIVmac variants, (35)). Given that other
viruses can use rmCXCR6 in vitro ((5) and data not shown), imposing use of rmCXCR6 use onto
SIVmac is likely biologically feasible. If such passaging is not sufficient to eliminate CCR5 use,
the virus could be further modified to ablate CCR5 binding (if possible), or, infections could
proceed in the presence of the CCR5-blocker maraviroc. This CXCR6-restricted infection could
mimic natural host infection by forcing the virus into more replenishable CXCR6-expressing
subsets, such as Tem, and protecting cells such as Tcm that don’t express CXCR6 in RM. I
hypothesize that such an infection in rhesus macaques would have high viremia due to sufficient
CXCR6+ target cells, but less pathogenicity than a typical SIVmac infection due to lack of
infection of critical subsets such as Tcm that infrequently express CXCR6.

Any residual

pathology could be due to additional mechanisms to modulate the immune system in the
presence of SIV infection that non-natural hosts have not been pressured to evolve, and this
macaque model could be used to define such mechanisms.

While data clearly show use of CXCR6 for entry by SIVsmm and SIVagmSab ex vivo (4) (Chapter
2), many questions remain regarding the use of these coreceptors in vivo, and the relative
contribution each plays in natural host SIV infection. To determine the relationship between
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CXCR6 expression and in vivo infection of SM or AGM, CD4+ T cells from chronically infected
animals could be sorted into four groups based on single, double or no CCR5 and CXCR6
expression and cell-associated viral DNA quantified.

This would identify which coreceptor-

expressing subsets are more frequently targeted by SIV in vivo. (Reduced viral loads of CCR5null sooty mangabeys suggest that CCR5+ CXCR6- cells do serve as targets in these animals.
(2)) Previous studies have identified decreased cell-associated viral DNA in sooty mangabey
Tcm, as compared to sooty mangabey Tem and rhesus macaque Tem (12); sorting by both
memory markers and coreceptor expression would reveal the contribution of CXCR6 use to this
difference.

The CXCR6 expression data shown here (Chapter 4) was performed on cells from SIV negative
sooty mangabeys. Monitoring CXCR6 expression over the course of an SIV infection would
indicate if coreceptor expression is actively modulated or changes as a consequence of infection,
thus altering what cells serve as targets. For CCR5, previous studies have shown that the
proportion of CCR5+ CD4+ T cells increases slightly in acute infection of sooty mangabeys, but
less so than the drastic increase observed in rhesus macaque infection (12). In chronic infection
of SM, the proportion of CCR5+ CD4+ T cells is reduced (36). However, current regulations
against experimental infection of SM make it impossible to carry out a time course study in
experimental SIVsmm infection. However, such a study could be performed in African green
monkeys (AGM) after defining CXCR6 expression in this host, or by comparing coreceptor
expression levels between populations of chronically infected and uninfected sooty mangabeys.

Use of coreceptors in addition to CXCR6
While CCR5 and CXCR6 were the most robust coreceptors in vitro for both SIVsmm and
SIVagmSab, blocking entry through CCR5 and CXCR6 was insufficient to completely block
replication of both viruses (4) (Chapter 2). We think this is likely due to the inability of maraviroc
and CXCL16 to completely block entry through CCR5 and CXCR6, respectively. However, it
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could also be due to the use of coreceptors in addition to CCR5 and CXCR6. In particular,
GPR15 was used by both viruses in vitro, albeit more efficiently by SIVagmSab. GPR15 has no
known ligand or small molecule inhibitor, so we have been unable to test use of this coreceptor
directly. However, advances in gene-editing technologies may permit future studies where use of
these three coreceptors is interrogated further by gene deletion from primary lymphocytes.
Staining of lymphocytes from several SM and RM demonstrated GPR15 expression on CD4+ T
cells, which was largely independent of CCR5 and CXCR6 expression (data not shown). This
finding is congruous with studies of human coreceptor expression, where CXCR6 and CCR5
were expressed by Th1 cells (30, 37) and GPR15 was expressed by Th2 cells (38). However,
there is evidence that GPR15 may not function as a coreceptor on primary cells even if it
functions in transfected cells: GPR15 is robustly expressed on rhesus macaque CD4+ T cells,
and SIVmac uses rmGPR15 efficiently in vitro in transfected cells, but does not use it to enter RM
CD4+ T cells ex vivo or appear to use it in vivo (39-41). This suggests that at least for SIVmac,
expression of CD4 and GPR15 is not sufficient to render a CD4+ T cell a target. A possible
explanation could be if Th2 cells were intrinsically less permissive to SIVmac infection.
Alternatively, there may be currently unappreciated differences between GPR15 structure or posttranslational modification when expressed in vitro vs. endogenously, therefore underscoring the
importance of confirming pathway use by blocking entry in lymphocytes.

Alternative coreceptor use by untested SIVs
SIVsmm, SIVagm, and SIVmus represent three distinct lineages of natural host SIVs that
diverged at least hundreds of thousands of years ago, suggesting that CXCR6 use by natural
host SIVs is longstanding, in addition to widespread (1, 42). Other distinct but untested viruses
include SIVmnd, SIVolc and SIVlho that infect mandrills, olive colobus monkeys and l’Hoest’s
monkeys, respectively. Defining the coreceptor usage patterns of these SIVs akin to studies in
this thesis would flesh out the breadth of CXCR6 uses among natural host SIVs.
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Cross species transmission, coreceptor restriction and the emergence of
pathogenesis
The lack of pathogenesis of SIV infection of natural hosts is thought to be the product of
prolonged coevolution between virus and host. Thus, the emergence of pathogenesis when an
SIV infects a naïve host is not unexpected. Two major examples of this pattern exist: One,
SIVsmm infection of rhesus macaques resulted in SIVmac, the main animal model for HIV-1
infection of humans (43). Two, a virus of the lineage to which SIVmus belongs crossed into
chimpanzees (along with SIVrcm that contributed the 5’ half of the genome) giving rise to
pathogenic SIVcpz (44, 45). SIVcpz then crossed the barrier into humans, giving rise to HIV-1,
which is even more pathogenic in its respective host than SIVcpz is believed to be (46, 47).

Of note, cross-species transmission events (both experimental and in the wild) do not always
result in immunodeficiency. For example, experimental infection of RM with SIVagmSab results in
control of the virus (48). Also, SIVagmSab DNA was isolated from a Patas monkey infected in the
wild, and a follow-up experimental infection of Patas monkeys with SIVagmSab resulted in a
natural host phenotype (49, 50). Patas monkeys are characterized by a low frequency of CCR5+
CD4+ T cells, suggesting that their coreceptor expression patterns and therefore virus targeting
may parallel natural hosts of SIV even though there presently is no identified circulating SIV in
this species.

For SIVmac and SIVcpz/HIV-1, a common outcome of their origin in cross-species transmission
is restriction to use of CCR5 as a coreceptor from use of both CCR5 and CXCR6. Yet, the origin
of this phenotype differs between these two cross-species transmission events. For SIVmac, the
inability to use rmCXCR6 efficiently for entry originates from the sequence of the coreceptor, as
the R31 residue encoded in the N-terminus renders rmCXCR6 a poor coreceptor for SIVmac
(51). In vitro, SIVmac can use CXCR6 of other species for entry (4, 51), and this is consistent
with the correlation between the ability to use CXCR6 and the lack of a restrictive V3 loop Pro
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residue (Chapter 3). However, I found that the inability to use CXCR6 by SIVcpz is conferred by
the virus, not the host, as it cannot use CXCR6 of any species for entry and this env encodes the
CCR5-restrictive V3 loop Pro residue, which is also true for HIV-1.

The contribution of restriction to CCR5 use to pathogenesis likely lies in the fact that CCR5 is
much more highly expressed on critical CD4+ cell subsets in non-natural hosts than natural
hosts, defining these cells as targets, unlike the limited CCR5 expression on such subsets
observed in natural hosts. The infrequent expression of CCR5 observed in natural hosts is
hypothesized to have evolved as a mechanism to coexist with the virus; of course, humans and
macaques species have not had prolonged virus-mediated pressure to acquire this mechanism.
However, a cohort of highly viremic nonprogressing children was recently identified in Africa, and
a correlate of this phenotype was low infection of CD4+ Tcm, concomitant with reduced CCR5
expression (22).

Use of CXCR6 and other coreceptors by their viruses has not yet been

determined. Studies of P.t. verus chimpanzees, which do not harbor an endemic SIV, have found
an intermediate level of CCR5 on their CD4+ T cells (20). This suggests that pressure in addition
to lentivirus coreceptor use can limit CCR5 expression. It is unknown if similar CCR5 expression
is also found in P.t. troglodytes and P.t. schweinfurthii that do carry SIVcpz.

While the host-driven inability of SIVmac to use CXCR6 is quite simple, a more complicated
question is why SIVmus would have lost use of CXCR6 upon cross-species transmission into
chimpanzees, particularly because use thereof is widespread among SIVs and is associated with
an expanded range of target cells. Loss of CXCR6 use as SIVcpz emerged could have been a) a
coreceptor-independent consequence of adapting to a new host; b) a stochastic event associated
with lack of selection pressure to retain CXCR6 use; or c) a necessary, coreceptor-dependent
step in the evolution of the virus.
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To address the first option, the observation that SIVmus cannot use chimpanzee CD4 for entry
suggests that the barrier towards cross-species transmission may have been high for envs of this
lineage (Chapter 3). It’s possible that in the adaptation to use cpzCD4, restriction to use of CCR5
by env occurred in tandem. This could have happened incidentally, due to high selection pressure
on env in general, or perhaps a necessary consequence of generating Env that could bind
chimpanzee CD4 and still maintain a viable structure. An experiment to address this could be to
generate replication competent SIVmus (and other SIVs of that lineage) and passage it on
chimpanzee CD4+ T cells, or a cell line expressing chimpanzee CD4 and coreceptor. Such
passaging could promote affinity for the chimpanzee CD4, and in vitro analysis of coreceptor
usage could determine whether the resulting virus had restricted coreceptor usage as a result of
the changes needed to adapt to chimpanzee CD4.

A second explanation could be that use of CXCR6 by the SIVcpz forerunner was no different than
use of CCR5, and therefore lost without selection pressure as SIVcpz emerged. This would be
most plausible if CCR5 and CXCR6 were frequently coexpressed on chimpanzee lymphocytes,
as they are on human cells, therefore rendering entry through CXCR6 a redundant pathway that
offered no selective advantage for the virus.

Staining of chimpanzee cells for coreceptor

expression would inform this possibility. Similarly, if chimpanzee cells infrequently express
CXCR6, pressure to retain use of this coreceptor would have been minimal.

However,

chimpanzee cells are not available for research studies to test these points directly.

A third possibility is that restriction to CCR5 explicitly was a necessary event for SIVcpz to
emerge. It’s possible that an increase in affinity to cpzCCR5 was required for efficient entry, and
use of cpzCXCR6 was lost as a consequence. However, I found that SIVmus could readily enter
through cpzCCR5, suggesting that the need to adapt to cpzCCR5 was not a source of
evolutionary pressure. To test this thoroughly, however, it would be useful to test efficiency of use
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more directly, for example by titrating cpzCCR5 in vitro, akin to the SIVagmSab experiments in
Chapter 2.

Selection for use of CCR5 over CXCR6 could also occur due to post-entry events; this would
require a fitness advantage for viruses that entered via cpzCCR5 over cpzCXCR6. This could
occur through two possible mechanisms: a) CCR5+ cells are distinct from CXCR6+ cells and are
better at supporting viral replication, independent of coreceptor engagement; or b) binding of
CCR5 by Env and subsequent signaling could promote a cellular environment that supports virus
replication better than CXCR6-Env interactions. (This second mechanism could occur whether
CCR5 and CXCR6 are coexpressed or not.) Given the sequence divergence of these two
chemokine receptors, distinct downstream signaling events are plausible and will be discussed in
more detail later in this section. Again, staining chimpanzee CD4+ T cells would be required to
determine whether or not CCR5 and CXCR6 are coexpressed in this host. If they are differentially
expressed, the susceptibility of distinct populations of coreceptor expressing cells could be
measured by infecting lymphocytes with GFP reporter viruses while staining for coreceptor
expression and measuring relative infectivity of CCR5 or CXCR6 expressing populations.

Lastly, the pressure against CXCR6 use could have been driven by the chimpanzee immune
system, rather than requirements for virus replication in a new host. In humans and macaques,
adaptive immune pressure against CXCR4-using viruses has been observed (52, 53), and a
similar pressure could be exerted on CXCR6-using viruses in chimpanzees. It is not clear if or
why such pressure would exist in chimpanzees but not in natural host monkeys. However, this
would be difficult to investigate as experimental infection of chimpanzees is prohibited.

An additional challenge to studying SIVcpz restriction to CCR5 use is that the originating crossspecies transmission event is believed to have occurred one time, unlike SIVsmm into humans
that has occurred at least eight times, and SIVcpz into humans that has occurred four times (54).
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Multiple cross-species transmissions allow comparison of requirements for transmission,
particularly when the resulting viruses vary in fitness in their new host (55).

However, no

comparison exists for the emergence of SIVcpz. The occurrence of only a single transmission
event could reflect a high barrier to cross species transmission. However, SIVgsn/mus/mon also
are less prevalent in their hosts than other viruses that have crossed the species barrier, so fewer
relative exposures have likely been made (56).

Also, recombination between SIVrcm and

SIVmus could have been necessary for emergence of SIVcpz, with the presumably low likelihood
of coinfection with two distinct but compatible viruses.

CXCR6-using HIV-1 variants are rarely identified (57). Coreceptor use of HIV-1 beyond CCR5
and CXCR4 is infrequently investigated, so extensive analysis of CXCR6 use is lacking.
However, the CXCR6-incompatible V3 loop Pro is strongly conserved among HIV-1 variants (58).
Thus, I speculate that env of HIV-1 (and SIVcpz) has evolved such that the barrier to regaining
use of CXCR6 as a coreceptor is high. The data demonstrating the inability to confer CXCR6 use
to SIVcpz supports this (Chapter 3) but further attempts to do so would be warranted to draw this
conclusion. Thorough analysis of CXCR6-using HIV-1 variants could elucidate determinants of
CXCR6 usage by HIV-1, as could passaging HIV-1 and/or SIVcpz to promote adaptation to
CXCR6 as previously described. Alternatively, there could be human-specific selection pressure
against CXCR6-using HIV-1 variants, such as immune pressure (as is the case for CXCR4-using
variants, (52, 53)) or cellular factors that restrict their replication that don’t exist in natural hosts.
Investigation of the contribution of CXCR6 use by HIV-2, which can use CXCR6 in vitro (59),
would inform the human pressures on CXCR6-using viruses.

Properties of the entry coreceptor CXCR6
All SIV coreceptors identified thus far, including CCR5 and CXCR6, are 7 transmembrane G
protein coupled receptors (7TMRs). While these molecules are quite distinct at the amino acid
level (many sharing no more than 25% amino acid identity with each other) they do share several
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structural and amino acid level features. As their name suggests, these molecules cross the
plasma membrane seven times, and all have several Tyr residues in the N terminal domain. For
CCR5, it is known that sulfation of several of these Tyr is essential for interaction with the HIV
envelope (60). Studies of CCR5 and CXCR4 have revealed that this N-terminal domain interacts
with the bridging sheet and the base of the V3 loop of Env, while the second extracellular loop
(ECL2) interacts with the V3 loop of Env (61). Although CXCR6 and other alternative coreceptors
have not yet been analyzed, this two-part mechanism is likely conserved. Future experiments
involving swapping domains between CXCR6 and a 7TMR that is not used as a coreceptor could
easily parse out which CXCR6 domains are necessary for coreceptor use. The fact that a single
amino acid change (R31) in the N-terminus of rmCXCR6 renders it a poor coreceptor for SIVmac
suggests that the N-terminus is an important determinant of CXCR6 use, at least for SIVmac (51).
However, the N-terminus of CXCR6 varies distinctly between musCXCR6 and cpzCXCR6, yet
SIVmus can use both for entry (albeit musCXCR6 more robustly) (Chapter 4) (Figure 5.2).
Furthermore, SIVmus entry through musCXCR6 is not seemingly hindered by the same R31 that
makes rmCXCR6 a poor coreceptor for SIVmac (Chapter 4). Therefore, requirements for use of
this domain might vary between viruses, or specific regions of the N-terminus might be more
important for CXCR6 use or CXCR6 structure than others.

CXCR6 also has several features that distinguish it from other 7TMRs such as CCR5.
Structurally, many 7TMRs have four extracellular Cys residues, which form disulfide bonds
between the N-terminus and ECL3, and ECL1 and ECL2. In contrast, CXCR6 lacks Cys residues
in the N-terminus and ECL3, thus limiting the coreceptor to one disulfide bond and likely resulting
in a more flexible structure (Figure 5.2). As described in Chapter 3, Envs that use CXCR6 also
have a structural signature; the V3 loop that interacts with the coreceptor encodes Ala, Ser or
Thr, instead of the rigid Pro observed in SIVcpz and HIV-1 that is associated with the inability to
use CXCR6. Further studies are warranted to determine how these features contribute to
CXCR6-Env interactions.
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Secondly, most 7TMRs signal through a DRY domain in the second intracellular loop that
interacts with G proteins; CXCR6 has a DRF motif instead, which allows association with a
broader range of G proteins and may promote adhesion of CXCR6-expressing cells to cells
expressing the CXCR6 ligand CXCL16 on their surface (62, 63). This could result in distinct postentry events due to coreceptor-mediated signaling by Env.

Data suggests that HIV-1 Env-

mediated signaling through CCR5 is not necessary for entry (64-66), while HIV-1 Env binding to
CXCR4 promotes cytoskeleton remodeling to permit infection of resting cells (67). Irrespective of
the requirement for entry, HIV-1 and SIVmac Env-coreceptor interactions do induce intracellular
signaling (68-70), and engagement of CCR5 has been suggested to promote virus replication by
augmenting CD4+ T cell activation (70). Given the distinct intracellular signaling motifs between
CXCR6 and CCR5, its possible that SIV entry via CXCR6 initiates distinct signaling cascades,
with distinct cellular consequences, than does entry via CCR5. So far, studies of CXCR6
signaling have identified that CXCL16 binding only weakly induces chemotaxis, unlike robust
chemotaxis observed for CCR5 (31, 63, 71). Analysis of the phosphoproteome post entry through
these two coreceptors could elucidate effects of distinct coreceptor use and suggest whether
entry via one or the other altered cellular activity in a way that would impact virus replication.
Such a study would be aided by the generation of identical SIVs that only varied in their capacity
to use either CCR5 or CXCR6 for entry.

Studies of humans and rats have suggested that CXCR6 serves as an extralymphoid homing
receptor; in humans, CXCR6 is rarely coexpressed with the lymphoid homing marker CCR7 (30),
and rat lymph node CD4+ T cells rarely express CXCR6 (31). Likewise, I found that RM and SM
cells lacking CCR7 (Tem in this study) were enriched for CXCR6 expression, while cells
expressing CCR7 (Tn and Tcm) had little to no CXCR6 expression (Chapter 4), although tissues
have yet to be analyzed. Stimulation of CD4+ T cells has demonstrated that most CXCR6+ cells
have a Th1 phenotype (30). Additionally, many studies have identified an expansion of CXCR6+
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cells at sites of inflammation in humans, such as rheumatoid arthritis (72) and colitis (73), as well
as in cancer of tissues such as the liver (74), prostate (75) and gut (76), suggesting that CXCR6+
cells are immune effectors. In particular, expression of CXCR6, as well as its ligand CXCL16, is
often associated with increase tumor invasion and metastasis (77). The ligand CXCL16 is unique
in that it exists in both membrane-bound and soluble forms, and CXCL16-expressing cells include
antigen presenting cells and epithelial cells (78-80). Studies of human molecules suggest that
CXCR6-CXCL16 binding mediates retention of CXCR6+ cells at effector sites (63, 81, 82). Thus,
CXCL16 expression could also contribute to localization of CXCR6+ target cells in natural hosts,
and CXCL16 expressing cells ought to be defined as well.

In Conclusion
Analyses of SIVagmSab and SIVmus described in this thesis, in addition to published data
regarding SIVsmm and SIVagmVer, support a paradigm of CXCR6 use as a common feature of
natural host viruses. In contrast, pathogenic SIVcpz cannot use CXCR6, like HIV-1, suggesting
that use of this coreceptor was lost upon cross-species transmission and the emergence of
SIVcpz. While transfer from the low-CCR5 environment of natural hosts to the higher-CCR5
environment of non-natural hosts would have enabled a virus to be CCR5-restricted yet fit, further
studies will be necessary to elucidate the reasons that CXCR6 use was lost. Nevertheless, a
consequence of this coreceptor transition would be targeting of virus to distinct CD4+ cell
populations, with distinct outcomes on immune function and homeostasis. Future experiments will
delineate the precise consequences of SIV entry through CXCR6, particularly in regard to target
cells and anatomic niches defined by this coreceptor, as well as virus-mediated signaling events.
As CCR5 gene deletion of CD4+ T cells of HIV-1 infected patients to confer resistance becomes
a possible therapy (83, 84), it is conceivable that the ability to use other coreceptors (beyond
CXCR4) might be acquired. Thus, fully understanding virus- and host-mediated determinants of
target cells is essential. Furthermore, African humans are regularly exposed to SIV+ nonhuman
primates, and understanding the barriers to cross-species transmission will allow full
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comprehension of the risk of interaction with various primates (56). Therefore, continued studies
of the contribution of CXCR6 use to natural host SIV infection are critical to maximize our
understanding of HIV pathogenesis and cross-species transmission.
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Figures
Normal SIV-host relationship:
SIVsmm/SM & natural hosts

Infection of an unadapted host:
HIV-1/human, SIVmac/RM

CXCR6-mediated targeting
with limited CCR5 expression

CCR5-mediated targeting with
common CCR5 expression

Key CXCR6+
target cells
(Tem?)

Tscm
TH17

Tcm
Tfh

Lymphoid tissue infection & damage
• Disrupted CD4+ T cell homeostasis
Chronic immune activation

Viremia with
CD4+ T cell loss

Viremia without
CD4+ T cell loss

Figure 5.1: Model for divergent coreceptor entry pathway use in natural and non-natural HIV/SIV
hosts that may contribute to distinct infection outcomes. Left: Use of CXCR6 in the setting of restricted
CCR5 expression in natural hosts targets SIV to CD4+ T cells that support viremia without CD4+ T cell loss
and immunodeficiency. Right: Use of CCR5 in pathogenic SIV and HIV infections where CCR5 expression is
plentiful results in targeting of CD4+ T cell subsets that compromise the immune system and cause CD4+ T
cell loss and immunodeficiency.
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Figure 5.2 Sequence alignment of CXCR6 from SM, AGM, MUS, GSN, RM and CPZ. Highlighted
features include: N terminal Tyr residues (residues 4, 7, or 6,10 (CPZ only)); predicted N-linked glycosylation
site (residue 17); residue 31 that codes for an Arg in RM and MUS instead of the more common Ser and
renders RM CXCR6 a poor coreceptor (ê); extracellular Cys residues that form a disulfide bond (residues
103 and 181); and the G protein signaling motif DRF (residues 127-129). ★ indicates the approximate
location of Cys residues often found in other 7TMRs, including CCR5, that can form a second disulfide bond
but which are lacking in CXCR6. Boxes represent transmembrane domains predicted by the TMPRed
program. The AGM CXCR6 allele shown here has been isolated from both sabaeus and vervet AGM.
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